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ABSTRACT 
Proper functioning of endocrine cells is crucial for organismal homeostasis.  The 
underlying mechanisms that fine-tune the amount, and the timing of hormone 
secretion are not clear.  JIP1 / MAPK8IP1 (JNK interacting protein 1) is a scaffold 
protein that mediates cellular stress response, and is highly expressed in 
endocrine cells, including insulin secreting b-cells in pancreas islets.  However, 
the role of JIP1 in b-cells is unclear. This study demonstrates that b-cell specific 
Jip1 ablation results in decreased glucose-induced insulin secretion, without a 
change in Insulin1 and Insulin2 gene expression.  Inhibition of both JIP1-kinesin 
interaction, and JIP1-JNK interaction by genetic mutations also resulted in 
decreased insulin secretion, suggesting that JIP1 may mediate insulin vesicle 
trafficking through interacting with kinesin and JNK.  Autophagy is a cellular 
recycling mechanism and implicated in the b-cell function.  Both JIP1 and JNK 
are proposed to regulate autophagy pathway.  However, it is unclear whether 
JNK plays a role in the promotion or suppression of autophagy.  The findings of 
this study show that JNK is not essential for autophagy induction, but can 
regulate autophagy in a cell and context specific manner.  The results in this 
thesis implies a mechanism that link cellular trafficking and stress signaling 
pathways in the regulated hormone secretion.  In addition to the known role of 
JIP1 in metabolism and insulin resistance, this finding may also be relevant to 
endocrine pathologies.   
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CHAPTER 1: INTRODUCTION 
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1.1 The endocrine system and autophagy in metabolism 
1.1.1 Regulation of energy homeostasis by the endocrine system 
Regulation of energy storage, mobilization, and consumption is crucial for 
complex organisms to ensure proper functioning of vital organs.  The brain is 
dependent on glucose for its energy use, although during prolonged fasting it can 
utilize ketone bodies in addition to glucose [1].  On the other hand, very high 
glucose levels can cause hyperosmolar crisis, which is a life-threatening 
condition [2].  Moreover, a prolonged increase in glucose levels can cause organ 
and tissue dysfunction, such as the endothelial pathologies observed in diabetic 
patients [3].  Thus, it is crucial for an organism to maintain its blood glucose level 
at the physiological range, which is ~80-120 mg/dl. 
Multiple organs co-operate to regulate the utilization of fuels (glucose, fatty 
acids, and amino acids) during fasting and feast [4].  Fasting and feast represent 
two extreme metabolic states where an organism needs distinct responses.  The 
neuroendocrine system regulates the switch from the anabolic state during feast 
to a katabolic state during fasting; and vice-versa [5-8].  Increased insulin after a 
meal consumption directs the fuel, in the form of glucose, amino acids, and lipids 
to the tissues such as fat, liver, and muscle; where they are used, or stored.  In 
fed state, protein synthesis is also increased in parallel with growth [9]. 
In the fasting state, mostly the liver can provide its stored glucose to the 
circulation for utilization by other tissues.  Elevated circulating glucagon levels in 
fasting state increases hepatic glucose production [10].  Mobilization of the liver 
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glycogen depots provides the majority of the blood glucose during the first hours 
of fasting. Gluconeogenesis is gradually increased and becomes the only source 
of glucose after ~24 hours of fasting, when liver glycogen depots are depleted 
[11].  Although other tissues, such as the muscle, can store glycogen, they 
cannot mobilize it to the circulation since they lack glucose 6-phosphatase, which 
catalyzes the final dephosphorylation step of glucose that is required for the 
export of glucose [12].  However, muscle and fat contribute to gluconeogenesis 
by providing amino acids, fatty acids, and glycerol to the liver [13].  Glucogenic 
amino acids can be catabolized to pyruvate, which is the main substrate of 
gluconeogenesis, while fatty acid oxidation mainly provides the energy for 
gluconeogenesis.  Fatty acids can be utilized as fuel by many tissues, especially 
during prolonged starvation. 
One exception that can overcome the effects of high insulin during feast is 
the adrenergic “fight or flight” response [14].  Increased adrenergic signaling 
suppresses insulin secretion and action, and induces glycogenolysis and 
gluconeogenesis in the liver in addition to the fatty acid mobilization from fat. 
Thus, the availability of fuel becomes the highest for vital tissues for maximum 
performance capacity in a life-threatening situation [15, 16].  On the other hand, 
prolonged stress and adrenergic stimulus can adversely affect the blood glucose 
levels, especially in diabetic patients [17]. 
  4 
The neuroendocrine system facilitates the communication between fat, 
muscle, and liver to fine-tune energy balance during feast, fast, and stress 
conditions (Figure 1.1.). 
 
 
Figure 1.1. A summarized presentation of energy regulation by 
neuroendocrine system. 
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1.1.2. Endocrine dysfunction and obesity 
In obesity, energy balance is biased towards the increased lipid storage 
and decreased energy expenditure.  Although the main etiology of the worldwide 
obesity pandemic is increased food consumption and sedentary lifestyle, there 
are various diseases that can cause obesity, including endocrine tissue 
dysfunction. 
For instance, Cushing syndrome, where there is elevated circulating 
cortisol, is presented by an increase in the abdominal obesity, in addition to the 
other effects of high cortisol [18, 19].  Cushing syndrome is mostly caused by a 
pituitary adenoma, secreting adrenocorticotrophic hormone (ACTH).  Although, 
less frequently, a cortisol secreting adrenal tumor can also cause Cushing 
syndrome. 
Insulinoma, where there is an uncontrolled increase in the circulating 
insulin levels, can also cause obesity [20].  In this case, increased food 
consumption to compensate the hypoglycemic effect of the increased insulin 
levels is the main cause of the obesity. 
Although adipose tissue is best known for its fat storage capacity, 
adipocytes also have endocrine functions and can signal to the other tissues to 
regulate the energy metabolism.  Leptin, a hormone secreted from adipose tissue 
after a meal targets the hypothalamus to inhibit further food intake [21].  Genetic 
deletion of leptin, or the leptin receptor, results in hyperphagia and obesity in 
humans and rodents [21-25]. 
  6 
In conclusion, hormonal balance is crucial for a healthy energy 
distribution. Thus, over-functioning or under-functioning of endocrine cells can 
contribute to the metabolic dysregulation and related diseases. 
 
1.1.3. Obesity-induced insulin resistance, and beta-cell dysfunction 
One of the important complications of obesity is the increased insulin 
resistance that is associated with hyperinsulinemia and may progress to type-II 
diabetes.  However, the mechanism of the insulin resistance in obesity is 
incompletely understood [26]. 
In the abdominal obesity, fat deposition in the visceral space and ectopic 
organs, such as the liver is increased.  This specific localization of fat deposition 
is implicated in the metabolic dysfunction of obesity [27]. Overexpansion of the 
fat depots may cause an uncontrolled release of free fatty acids, accompanied by 
chronic inflammation, which can contribute to the increased insulin resistance in 
obesity [28, 29]. 
Progressive obesity-induced hyperinsulinemia, and insulin resistance can 
result in islet expansion of islets and eventually b-cell dysfunction.  Moreover, 
increased circulating lipids and inflammatory cytokines in obesity can also have 
adverse effects on beta-cell function [30-33].   
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1.1.4. Autophagy and energy homeostasis 
Similar to organismal fuel management, a cell can react to the 
environmental nutrient status and redirect its fuel and resources to necessary 
cellular pathways.  Autophagy is a cellular self-recycling mechanism where a 
portion of the cytoplasmic content is targeted to the lysosomal pathway for 
degradation [34].  This process can be selective, such as mitophagy, where 
mitochondria is selectively targeted for the autophagosomal degradation.  Or it 
can be non-selective, termed macro-autophagy.   For the rest of the text by 
“autophagy” I will refer to macro-autophagy. 
Starvation-induced autophagy is important for the survival of the cell in a 
nutrient deprived environment, and is regulated by the energy sensors of the cell, 
such as the mTOR/AMPK (mammalian target of rapamycin/AMP Kinase) 
pathway[35] (Figure 1.2.).  Many ATG (autophagy related gene) proteins 
cooperate to regulate the initial double membrane formation which captures the 
cytoplasmic content for targeting to lysosome [36, 37]. 
Autophagy contributes to overall organismal development by regulating 
cellular catabolic processes [38, 39].  It is implicated in many diseases, such as 
cancer and neurodegeneration [40, 41].  Moreover, autophagy contributes to the 
organismal energy balance and is implicated in obesity and endocrine cell 
function [42, 43].  For instance, lipophagy, a specific form of autophagy that 
recycles lipids, can regulate cellular lipid metabolism [44].  Systemic decrease in 
autophagy in mice with heterozygous deletion of Atg7 (autophagy related gene) 
  8 
resulted in aggregated progression of obesity-induced diabetes, suggesting that 
autophagy is required for the organismal response to the metabolic stress [45]. 
 
 
 
Figure 1.2. Regulation of autophagy by energy sensing mTOR/AMPK 
pathway. 
 
 
However, it is possible that in a tissue specific context, decreased 
autophagy can both promote or inhibit obesity.  For instance, the deficiency of 
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ATG7, an autophagy related gene, in the muscle and liver of mice results in 
decreased obesity and increased insulin sensitivity after a high fat diet challenge 
[46].  This effect was attributed to the mitochondrial dysfunction-induced FGF-21 
expression in the autophagy deficient tissues.  FGF-21 (fibroblast growth factor-
21) is known for its beneficial effects in obesity [47, 48].  On the other hand, 
ATG7 deficiency in POMC (Proopiomelanocortin) neurons in hypothalamus 
results in decreased a-MSH (a-melanocyte stimulating hormone) levels, and 
consequently decreased lipolysis in adipose tissue and increased obesity [49]. 
Autophagy is also implicated in endocrine cell function [43].  Beta-cell specific 
deletion of ATG-7 resulted in decreased insulin secretion, and impaired glucose 
tolerance in mice [50].  Autophagy deficient beta-cells were more prone to cell 
death, and ATG-7 deficiency resulted in decreased beta-cell mass in obesity [51, 
52].  Moreover, more recently, autophagy was implicated in the removal of old 
insulin vesicles and promotion of young insulin vesicle secretion [53]. These 
studies suggest that autophagy in b-cells may play a role in both insulin 
secretion, and the expansion of b-cell mass in response to metabolic stress. 
More recently, an interesting idea was proposed, where autophagosomes 
could target its content to the secretory pathway, rather than lysosomal 
degradation [54].  Although more research is needed to support of this concept, 
this mechanism may provide a previously unexplored area of cellular autophagy-
endocrine regulation bridge. 
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1.2 Stress signaling pathways in energy homeostasis 
 
1.2.1 MAPK pathways and cellular stress response 
Similar to complex organisms, cells constantly reshape their biological 
behavior in response to the changes in their dynamic environment.  These 
changes include molecular signals, as well as mechanical stress conditions such 
as pressure, stretch, or contact loss.  Among the molecular signals, circulating or 
paracrine-acting factors such as hormones, cytokines, growth factors, and 
cellular nutrients are among the most studied factors that result in a biological 
response in cells.  Mitogen activated protein kinase (MAPK) group represents 
JNK, p38 and ERK protein families which regulate cellular responses to these 
various extracellular signals (Figure 1.3.). 
MAPKs are evolutionarily conserved serine/threonine kinases, and are 
activated by a kinase cascade mechanism [55].  Thus, an extracellular stimulus 
results in phosphorylation and activation of a MAPK Kinase Kinase (MAP3K), 
which then phosphorylates and activates a downstream MAPK Kinases 
(MAP2K); lastly phosphorylation and activation of MAPK by MAP2K results in 
transcriptional or non-transcriptional changes that shape cellular response [56].  
With multiple upstream activators and downstream targets, as well as cross-
signaling, MAPK pathways are highly complex, thus require regulatory 
mechanisms, such as scaffold proteins, for selectivity and specificity. 
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Figure 1.3. A summarized presentation of MAPK signaling components, and 
relevant pathways. 
 
1.2.2 Role of MAPK pathways in metabolic regulation 
MAPK signaling modules can respond to environmental changes. 
Dysregulation of energy homeostasis results in the alteration of the extracellular 
signals such as circulating hormones and nutrients.  These changes can activate 
MAPK pathways, which also mediates cellular response to the metabolic 
dysregulation.  For instance, insulin stimulation can activate ERK, p38 and JNK 
in the of muscle of lean animals, while this activation was suppressed in obese 
animals [57].  Another example is that TNF-a, a cytokine that is increased in the 
circulation of obese organisms, can also induce the activation of all MAPK 
families [58]. 
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Accordingly, activation of the MAPK pathways in obesity is implicated in 
the alterations of the metabolic regulation.  The ERK pathway is implicated in the 
regulation of adipogenesis, and activation of ERK pathway can contribute to the 
progression of obesity and insulin resistance [59-61].  Additionally, p38 activation 
by MKK6 can mediate the metabolic regulation.  MKK6 deficient mice are 
reported to gain less weight after a high fat diet challenge, which was associated 
with increased brown adipose tissue thermogenesis [62]. 
In the context of metabolic regulation, JNK is the most extensively studied 
MAPK and is discussed in more detail in the following section. 
 
1.2.3 Role of JNK in metabolism and energy homeostasis 
 
1.2.3.1 Increased JNK activation during metabolic dysfunction 
In obese mouse models, JNK activation is increased in a variety of tissues 
such as fat, liver, and muscle; and obesity-induced JNK activation is implicated in 
the diet induced obesity progression and insulin resistance [63].  However, which 
changes in an obese organism result in the activation of JNK is still unclear.  
There are multiple mechanisms proposed for the widespread JNK activation 
observed in obesity, and it is possible that a collective effect of these 
mechanisms can contribute to the JNK activation. 
The increase in the circulating free fatty acids in obese individuals is 
implicated in obesity induced insulin resistance and beta-cell dysfunction [64-66].  
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Increased circulating free fatty acids in obesity is also proposed to be a 
mechanism for JNK activation.  In support of this idea, 3T3-L1 adipocytes, 
primary hepatocytes, and pancreas beta-cells showed increased JNK activation 
upon treatment with free fatty acids [67, 68].  Furthermore, treatment of MEF 
(mouse embryonic fibroblasts) with saturated fatty acids but not unsaturated fatty 
acids induced PKC (Protein kinase C) activity, which resulted in an increased 
MLK3 mediated JNK activation via SRC-VAV signaling [69-73].  Both MKK4 and 
MKK7 play role in this pathway [69, 71].  Concordantly, both MLK3 deficient [72], 
and MLK2,3 deficient mice showed decreased JNK activation after a high fat diet 
challenge, in addition to a decreased obesity and insulin resistance [70]. 
Increased inflammation and circulating cytokines in obesity is another 
factor that contributes to increased insulin resistance [74, 75].  These secreted 
cytokines can be another player to activate MLK-JNK pathway in obesity [76, 77]. 
Increased circulating basal insulin levels in an obese organism can be 
another mechanism that may mediate sustained JNK activation [78]. 
 
1.2.3.2 Contribution of JNK to diet-induced obesity and insulin resistance. 
JNK1 deficient mice are protected against obesity and insulin resistance when 
fed a high fat diet, suggesting a role for high fat diet-induced JNK1 activation in 
the progression of obesity [63].  The role of JNK1 activation in obesity and 
related metabolic dysregulation is a combined effect of JNK1 in adipose tissue, 
muscle, myeloid cells and central nervous system [79-81].  On the other hand, 
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JNK1 deficiency in liver increased obesity-induced liver steatosis (liver fat 
deposition), while JNK1 and JNK2 double deficiency in liver resulted in improved 
glucose homeostasis; suggesting that differential regulation of JNK1 and JNK2 
may have distinct roles in the liver [82, 83]. 
Previous studies using mouse models to study the role of the JNK 
pathway in metabolism are summarized in Table 1. 
 
Table 1.1. Gene deletion studies in mouse models that examine the role of JNK 
pathway in metabolism. 
	
	
Deleted Gene 
[ref] 
Targeted 
Tissue 
Metabolic Phenotype 
JNK1 (MAPK8) 
[63] 
Whole body Decreased obesity, increased insulin 
sensitivity. 
JNK2 (MAPK9) 
[63] 
Whole body No change in body weight or insulin 
sensitivity. 
JNK3 (MAPK10) 
[84] 
Whole body Increased obesity and increased food 
intake 
JNK1 [81, 85] Nervous 
System 
(Nestin-Cre) 
Decreased obesity. Increased energy 
expenditure via increased thyroid axis 
activity. 
JNK3 [84] Neurons 
(Pomc-Cre) 
No change in obesity or food intake. 
JNK3 [84] Neurons 
(Agrp-Cre) 
Increased obesity and increased food 
intake 
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Deleted Gene Targeted 
Tissue 
Metabolic Phenotype 
JNK3[84] Neurons 
(Leprb-Cre) 
Increased obesity and increased food 
intake 
JNK1, JNK2 [86] Pituitary Gland 
(Cga-Cre) 
Decreased obesity. Increased TSH 
expression caused by decreased Dio2 
expression and negative feedback 
inhibition. 
JNK1 [82] Liver 
(Albumin-Cre) 
Increased hepatic steatosis. Decreased 
glucose tolerance and increased insulin 
resistance. 
JNK1 [80] Adipose Tissue 
(Fabp4-Cre) 
Decreased fat mass, increased hepatic 
insulin action 
JNK1 [79] Muscle 
(Mck-Cre) 
No change in obesity, increased insulin 
sensitivity in muscle 
JNK1, JNK2 [83] 
 
Liver 
(Albumin-Cre) 
Improved glucose tolerance 
JNK1 [80] Myeloid Cells 
(LysM-Cre) 
No effect on diet-induced obesity and 
insulin resistance 
JNK1, JNK2 [87] Myeloid Cells 
(LysM-Cre) 
No change in obesity. Decreased obesity-
induced inflammation and increased 
insulin sensitivity 
 
Table 1.1. (Continued) Gene deletion studies in mouse models that examine the 
role of JNK pathway in metabolism.  Promoters of the Cre-Recombinase for the 
tissue specific gene targeting is indicated in the parenthesis. 
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The studies summarized above show that JNK has a broad effect on the 
regulation of energy metabolism.  Considering that JNK can target almost 
hundred proteins [88], it is of importance to evaluate the signal-specific 
interactors of JNK to understand the underlying mechanisms of its cell and 
context specific functions.  Scaffold proteins is discussed in the following 
sections, as a regulatory factor for the specificity of MAPK signaling pathways. 
 
1.3 JIP1, a scaffold protein in stress signaling, and its relevance to 
metabolism 
 
1.3.1 Signaling complex assembly by scaffold proteins 
The cell, as a multi-task unit, can regulate various internal obligations and 
processes, as well as extra-cellular stimulus-mediated responses, 
simultaneously, but at the same time, separately and remotely.  To achieve this 
regulation, compartmentalization of signaling molecules within their functionally 
relevant environment is essential [89-92]. 
Scaffold proteins provide such a regulatory mechanism by mediating 
signaling complex assembly.  Scaffold proteins can interact with multiple 
components of a signaling module and, bring them in proximity [89, 93-95].  In 
1994, the first example of this phenomenon was described in yeast, where Ste-5 
scaffold protein formed complex with stress signaling proteins, MAP3 Kinase 
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(Ste11), MAP2 Kinase (Ste7) and MAP Kinase(Fus3), to enhance mating-related 
signal transduction [96, 97]. 
Additional studies on a variety of scaffold proteins provided evidence that, 
the function of scaffold proteins in regulating signal transduction is more complex 
and multi-dimensional than merely being a signal-specific platform for protein 
interactions [55, 95].  For instance, ERK scaffold protein KSR can associate with 
Raf1 at the plasma membrane, and this localization is regulated by Ras in 
response to growth factor stimulus [98].  Ste-5 scaffold protein can also recruit 
assembled signaling complex to the cellular membrane [99-101]. 
In addition to compartmentalization, post-translational modifications of 
proteins in a signaling module can also provide an additional fine tuning to 
ensure proper timing and localization of a specific signal [89-92].  For instance, 
scaffold proteins possess multiple phosphorylation sites and, phosphorylation 
status of these sites can induce or inhibit scaffold mediated signal transduction in 
a context-dependent manner [102-104].  Thus, scaffold proteins can regulate not 
only complex assembly, but also localization and timing of the signal activation. 
Taken together, current knowledge about scaffold proteins advocates that, 
better understanding of their function can significantly improve our understanding 
of how the complex cellular signaling machinery works.  Importantly, with recent 
technological advancement, synthetic scaffold designs in the future may enable 
us to simulate or inhibit specific signals in a cell without deteriorating other 
cellular functions [105-108]. 
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1.3.2 JIP family of scaffold proteins 
The JIP family of scaffold proteins consist of 4 members, JIP1, JIP2, JIP3, 
and JIP4, which were all identified by their interaction with JNK [109-114].  JIP1 
and JIP2 are structurally similar and have a JNK binding domain close to the N-
terminus, in addition to SH3 and PTB domains near the C-terminus [109, 110].  
While JIP3 and JIP4 share many common structures among each other, they are 
structurally distinct from JIP1 and JIP2.  For instance, JIP3 and JIP4 have a 
putative transmembrane domain close to the C-terminus, which is absent in JIP1 
and JIP2 proteins. In addition, there are multiple coiled-coil domains and a 
leucine zipper domain close to the N-terminus of the JIP3 and JIP4 proteins [112, 
114] (Figure 1.4). 
 
 
Figure 1.4. Structural and functional features of the JIP family of scaffold 
proteins. 
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JIP proteins can functionally differ by their upstream kinase interactors, 
downstream targets, and additional interacting proteins.  For instance, while JIP1 
specifically activates JNK signaling and does not interact with other mitogen 
activated protein kinases (p38 and ERK), JIP2 can interact with p38 and promote 
p38 activation downstream of Rac signaling via interacting Tiam1 and RasGEF1 
[115, 116].  JIP3 can mediate LPS induced JNK activation via interacting with 
TLR4 and MEKK1 [117].  JIP4 can promote p38 MAPK activation through 
interacting with MKK3, and MKK6 [114].  Altogether, these represent examples of 
specific MAP kinase activation by distinct scaffold proteins.  Some important 
interaction partners of JIP family proteins with stress signaling pathway 
components are summarized in Figure 1.5. 
 
Figure 1.5. Cartoon representing a summary of selected interaction partners 
of JIP family scaffold proteins. 
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 In addition to interacting with stress signaling pathway components, all JIP 
proteins can interact with Kinesin Light Chain, and are implicated in the 
regulation of intracellular trafficking [114, 118-122].  The following sections will 
focus on JIP1 and its physiologic function. 
 
1.3.3 Genomic locus, and expression profile of MAPK8IP1/JIP1 
1.3.3.1 Mapk8ip1 genomic locus 
JIP1 is encoded by the Mapk8ip1 gene, located on chromosome 11 in 
human, and chromosome 2 in mouse (Figure 1.6. &1.7.) [123]. 
 
Figure 1.6. The scheme of the human Mapk8ip1 locus obtained from UCSC 
Genome Browser (GRCh38/hg38). 
 
 
Figure 1.7. The scheme of the mouse Mapk8ip1 locus obtained from UCSC 
Genome Browser (GRCm38/mm10). 
 
 
A specific JIP1 antibody detects two bands in the immunoblots of the 
mouse brain, which correspond to the ~90 and ~110 KD sizes.  This non-
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homogenous size of the JIP1 protein can be a consequence of the differential 
regulation of gene expression at the transcriptional and translational levels, in 
addition to the post-translational modifications.  However, it is unclear which end 
products correspond to the high and low molecular weight JIP1 proteins. 
For instance, the genes coding the JIP1 protein in human and mouse 
have two alternative exon-1 sequences with distinct start sites and 5’UTRs [124] 
(Figure1.1 &1.2).  The mouse Mapk8ip1 locus, different from human MAPK8IP1, 
has two alternative exon-3 splice junctions, long and short exon-3, which adds 
another variability to the Mapk8ip1 transcript (Figure 1.1. &1.2.).  Moreover, an 
in-frame ATG at the short exon-3 junction, with an ~10 nucleotide upstream 
internal ribosome entry site (IRES) consensus sequence may provide a possible 
translation start site for an alternative smaller protein [124].  This in-frame ATG is 
conserved in both mouse and human. 
It is yet to be discovered which coding sequences correspond to the 
differently sized JIP1 proteins.  Another remaining question is, what are the 
functional differences of these proteins in the context of stability, subcellular 
localization and specificity. 
 
1.3.3.2 JIP1 expression profile 
JIP1 protein is expressed in humans, rodents, Drosophila (APLIP1) and C. 
elegans.  During embryogenesis, JIP1 is localized to the growth cones of 
developing neurons and can be detected in the brain protein lysates as early as 
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day E15 [125].  Initial studies detected JIP1 expression in the brain, and the 
insulin-secreting beta-cells in adult mouse, rat, and human [109, 110, 123, 124, 
126].  This expression pattern is thought to be at least partially regulated by 
REST, a zinc finger transcription repressor expressed in many tissues except 
brain and endocrine cells [127].  REST can bind to the 21-bp RE-1 silencer 
element (NRSE) on the promoter region of the Mapk8ip1 gene 
(-229 to -209 base pair) and may contribute to the inhibition of the JIP1 
expression in the non-neuronal and non-endocrine cells [128]. 
Figure 1.8. Mapk8ip1 expression data obtained from Genotype-Tissue 
Expression Database (GTEx) [129]. The Y-axis shows gene expression level in 
Transcripts Per Million (TPM). The X-axis represents various tissues ordered by 
Mapk8ip1 expression level. 
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Additional studies showed JIP1 expression in other endocrine tissues, such 
as the pituitary gland [125, 130].  Moreover, current published deep sequencing 
data from various tissues show a low level or lack of JIP1 expression in many 
non-neuronal and non-endocrine tissues (Figure 1.8.) [129]. Examples of such 
tissues include but not limited to the muscle, liver, and whole blood.  Besides, 
additional endocrine tissues such as adrenal gland and testis also show robust 
JIP1 expression (Figure 1.8.) [129].  On the other hand, JIP1 expression can be 
observed in some non-neuroendocrine tissues such as the adipose tissue [71], 
urothelial epithelium [131] and the kidney (Figure 1.8). 
 
1.3.4 Interaction partners of JIP1 
JNK-interacting protein-1 (JIP1) was first identified in a yeast 2-hybrid 
screen via its interaction with JNK [109].  The following studies described the 
scaffolding function of JIP1, and its interaction with upstream kinases in the JNK 
pathway, MKK7 and MLK group of MAPKKKs [93, 132]. 
The JNK binding domain of JIP1 is located close to the N-terminus region 
[109].  Especially the four residues of JIP1, Arg-156, Pro-157, Leu-160, and Leu-
162, are important for the JIP1-JNK interaction [109].  The physical interaction 
between JIP1 and JNK is required for JIP1 mediated JNK activity enhancement 
[132, 133].  There are three JNK proteins, encoded by Mapk8 (JNK1), Mapk9 
(JNK2) and Mapk10 (JNK3) genes [134].  JIP1 can interact with all three JNK 
proteins with a higher affinity compared with JIP2 [110]. Additionally, alternative 
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splicing of the genes encoding the JNK proteins results in a total of ten JNK 
isoforms; four JNK1 (JNK1a1, JNK1a2, JNK1b1, JNK1b2), four JNK2 (JNK1a1, 
JNK1a2, JNK1b1, JNK1b2), and two JNK3 (JNK3a1, JNK3a2) [135]. The binding 
affinity of JIP1 is higher to all JNK1 and JNK3 isoforms, compared with the JNK2 
isoforms; except for the JNK2a1 isoform, which shows a higher affinity to JIP1 
compared with other JNK2 isoforms [110]. 
JIP1 can be phosphorylated on multiple sites and the phosphorylation 
status of JIP1 can contribute to the regulation of JNK signaling mediated by JIP1 
[136].  For instance, phosphorylation of JIP1-Thr103 by JNK can promote JIP1-
mediated JNK activation by regulating MLK3 dynamics [137, 138].  In addition, 
JIP1 can mediate free fatty acid-induced JNK activation through interacting MLK3 
[70, 71], SRC [69] and VAV [73]; and upon lipid stimulation, phosphorylation of 
JIP1 on Tyr429 and Tyr427 mediates lipid shaft localization of JIP1 and its 
interaction with SRC [73].  On the other hand, interaction of JIP1 with MKP7, a 
phosphatase, can act as a negative regulator of JIP1-mediated JNK activation 
[139]. 
JIP1 can also interact with AKT (Protein kinase B), which is a 
serine/threonine protein kinase implicated in various cellular functions including 
metabolic regulation, cell survival and motility [140].  It is proposed that JIP1 can 
promote AKT activation by interacting with the PH domain on AKT, and 
increasing PI3K dependent AKT activation under submaximal growth factor 
concentrations [141, 142].  The interaction of JIP1 with AKT does not require the 
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JNK binding domain of JIP1 [141].  However, overexpression of AKT can 
suppress JIP1-JNK interaction, and consequently decrease JIP1-mediated JNK 
activation [141-143].  These data suggest that the role of JIP1 in AKT and JNK 
activation is either mutually exclusive or competitive, or both. 
Notch can also inhibit JIP1-mediated JNK activation [144].  Notch is a cell 
surface receptor that is implicated in the regulation of cell faith and development 
[145].  Presenilin induces the cleavage of Notch1 by g-secretase to release 
Notch1-IC (Active intracellular domain) [146].  The cleaved intracellular domain of 
Notch can interact with the JNK binding domain of JIP1 and inhibit JIP1-mediated 
JNK activation [144].  It is suggested that the JIP1-Notch interaction also has an 
inhibitory effect on the Notch signaling.  In addition to the Notch, JIP1 can 
interact with RBP-Jk, which is a target of the active Notch-IC.  JIP1 interaction 
with RBP-Jk results in the retention of RBP-Jk in the cytoplasmic compartment, 
thus inhibiting its transcriptional effects.  Concordantly, Jip1-/- MEFs show 
increased Notch1 activity [147]. 
Another noteworthy interaction partner of JIP1 is the vaccinia virus protein 
B1K Kinase, and TAK1 (MAP3K).  B1R kinase can interact with JIP1; and this 
interaction can facilitate the JIP1-TAK1 interaction, which may play a role for the 
virulence [148].  This represents an example of how an external pathogen can 
use the scaffold proteins to alter the cellular functions in its own advantage. 
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JIP1 can interact with a wide-array of proteins implicated in multiple 
cellular functions, suggesting a central role for JIP1 in the regulation of cellular 
signaling (Table 1.2.) 
 
Table 1.2. Interaction partners of JIP1. (Please note that binging site information 
is mostly limited to co-expression and mutation analysis, thus may not reflect all 
specific residues that are important for interaction. 
JIP1-
interacting	
protein	[ref]	
Binding	site	on	
interacting	
protein	
Binding	site	on	
JIP1	
Functional	
Relevance	
Interaction	
with	other	JIP	
proteins	
JIP1	[109,	149]	 SH3	 SH3	 Cellular	stress	
response	
JIP2,3,4	[150]	
JNK	[109]	 C	
terminus[133]	
(aa	Glu339,	
Glu331)	
JBD	
(aa	156-162)	
Cellular	stress	
response	
JIP2,	JIP3	[112],	
JIP4	
MKK7b1	[132,	
133]	
N	
terminus[133]	
aa	146-246	
aa	283-660	
aa	200-
211[133]	
Cellular	stress	
response	
JIP2,	JIP3	[112]	
MLK2-3	[132]	 	 aa	471-660	 Cellular	stress	
response	
JIP2,	JIP3	[112]	
DLK	[132]	 N	
Terminus[133,	
151]	
(aa	Phe177,	
Leu397,	Asp398)	
aa	471-660	 Cellular	stress	
response	
JIP2	
HPK1	[132]	 Possibly	
indirect	
Possibly	
indirect	
Cellular	stress	
response	
-	
LZK	[152]	 Kinase	
Catalytic	
Domain	
C	Terminus	 Cellular	stress	
response	
-	
Src	Family	
[153,	154]	
Lyn,	Fyn,	cSrc,	
Yes	
SH2	Domain	 unknown	 Cellular	Stress	
Response	
-	
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JIP1-
interacting	
protein	[ref]	
Binding	site	on	
interacting	
protein	
Binding	site	on	
JIP1	
Functional	
Relevance	
Interaction	
with	other	JIP	
proteins	
VAV	[73]	 SH2	Domain	 unknown	 Cellular	stress	
response	
-	
SHIP2	[155]	 unknown	 unknown	 Cellular	stress	
response	
-	
MKP7	[139]	 aa	394-443	 C-Terminus	 Cellular	stress	
response	
JIP2	
c-Abl	[156]	 unknown	 unknown	 Axonal	Growth	
Cytoskeleton	
Organization	
-	
RhoGEF	[157]	 C	Terminus	
aa	1543-1615	
PTB	domain	 Cytoskeletal	
dynamics	
Actin	
organization	
-	
Tau	(MAP)	
[158]	
unknown	 unknown	 Cytoskeletal	
dynamics	
Alzheimer’s	
Disease	
-	
Kinesin	Light	
Chain	[118,	
119]	
TPR	
Coiled	
coil[159]	
C	Terminus	 Anterograde	
Trafficking	
JIP2,	JIP3,	JIP4	
[114,	120]	
Kinesin	Heavy	
Chain	[160]	
(KIF5)	
Stalk	and	tail	 Aa307-700	 Anterograde	
Trafficking	
	
ARP1	[150]	 unknown	 unknown	 Dynein	
mediated	
retrograde	
trafficking	
-	
P150glued	[160]	 C-Terminus	 aa	307-700	 Dynein	
mediated	
retrograde	
trafficking	
-	
Rab10	[161]	 unknown	 aa	283-649	 Vesicle	
transport	
Neuron	
polarization	
-	
AKT-1	[141]	
	
PH	Domain	
(aa	61-112)	
aa 287–487 
& 
aa 488–711	
Cell	survival,	
metabolism	
-	
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JIP1-
interacting	
protein	[ref]	
Binding	site	on	
interacting	
protein	
Binding	site	on	
JIP1 
Functional	
Relevance	
Interaction	
with	other	JIP	
proteins	
IRS1,	IRS2	
[150]	
unknown	 aa	282-470 Insulin	
Signaling	
JIP2	
RalGDS	[162]	 unknown	 unknown AKT	signaling	
Cellular	
metabolism	
-	
LRP2	[163]	 unknown	 PTD	domain	 Low	Density	
Lipoprotein	
receptor	
signaling	
JIP2	
Megalin	[163]	 unknown	 PTD	domain	 Low	Density	
Lipoprotein	
receptor	
signaling	
JIP2	
ApoER-2	[163,	
164]	
C-terminus	
(Isoform-
specific	proline	
rich	domain)	
PTD	domain	 Low	Density	
Lipoprotein	
receptor	
signaling,	
Endocytosis	
JIP2	
Pax2	[165]	
	
Unknown	 Unknown	 Development	
(Kidney,	optic	
cup,	etc.)	
-	
Notch1	[144]	 IC	domain	 JBD	 Cell	growth	
and	
differentiation	
-	
RBP-Jk	[147]	 Proline	Rich	
Domain	
C-terminus	
(SH3)	
Notch	
Signaling	
-	
APP	[166,	167]	 Cytoplasmic	
domain	(AID)	
PTB	 Alzheimer’s	
Disease	
-	
Viral	B1R	
Kinase	[148]	
unknown	 aa	282-660	 Vaccinia	Virus	
Virulence	
-	
TAK1	[148]	
	
unknown	 unknown	 Vaccinia	Virus	
Virulence	
-	
VRK2	[168]	 unknown	 aa	471-660	 IL1b	signaling	 -	
LC3B	[169]	 unknown	 aa	312-331	
(LIR	Domain)	
Autophagy	 -	
AnkyrinG	[150]	 unknown	 unknown	 Ion	channel	
regulation	
-	
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JIP1-
interacting	
protein	[ref]	
Binding	site	on	
interacting	
protein	
Binding	site	on	
JIP1	
Functional	
Relevance	
Interaction	
with	other	JIP	
proteins	
Heat	Shock	
Proteins	
HSP90,	HSP70	
[150]	
unknown	 unknown	 Stress	
Response	
-	
GRP58	[150]	 unknown	 unknown	 Stress	
Response	
Protein	folding	
-	
Proteosomal	
Proteins	
Adrm1,	Pad1	
[150]	
unknown	 unknown	 Proteosomal	
Degradation	
-	
 
Table 1.2. cont’d 
 
 
1.3.5 Physiological function of JIP1 in vivo and in energy homeostasis 
Thompson et al. suggested that homozygous JIP1 deletion results in early 
embryonic cell death. Thus, JIP1 deficient mice were not viable [170].  On the 
other hand, JIP1 deficient mouse lines established by two independent groups, 
Whitmarsh et al., and Im et al., were viable and fertile with expected Mendelian 
ratios [119, 171].  All three studies reported a complete ablation of both ~90 KD 
and ~110 KD JIP1 proteins.  However, Whitmarsh et al. and Im et al. targeted a 
smaller region around the exon3, while Thompson et al. targeted the complete 
Mapk8ip1 locus [119, 170, 171].  There is a predicted microRNA coding 
sequence (Mir7000) in intron4 of Mapk8ip1 (Figure 1.9.). 
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Figure 1.9. Mapk8ip1 exon4-exon5 region showing Mir7000 on intron 4. 
The scheme is obtained from UCSC Genome Browser (GRCm38/mm10). 
 
Moreover, a previously uncharacterized gene (1700029I15Rik) is located 
at ~75bp downstream of the 3’ end of the Mapk8ip1 gene (Figure 1.10.) [172].  
Thus, it is possible that the deletion of the complete Mapk8ip1 locus would affect 
multiple gene functions, which may contribute to the lethal phenotype observed 
by Thompson et al [170]. 
 
 
Figure 1.10. Mapk8ip1 exon12 and 3’UTR region showing the close localization 
of the annotated gene 1700029I15Rik.  The scheme is obtained from UCSC 
Genome Browser (GRCm38/mm10). 
 
 
JIP1 deficient mice established by Whitmarsh et al. and Im et al. did not 
show a growth abnormality but there was a protective effect of JIP1 deficiency 
under some stress conditions.  For instance, kainic acid (excitotoxic stress) or 
oxygen and glucose deprivation-induced JNK activation was suppressed in JIP1 
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deficient neurons.  Consequently, JIP1-deficient neurons were resistant to the 
stress induced apoptosis [119].  Moreover, JIP1-deficient mouse brains showed 
decreased infarct volume after ischemia-reperfusion, in addition to a decrease in 
the P-JNK levels, compared with WT mouse brains [171]. 
Earlier studies proposed that JIP1 is localized to the nucleus in b-cells and 
may promote GLUT-2 expression [126].  In addition, a S59N mutation in human 
Mapk8ip1/JIP1 locus was associated with a late onset type-II diabetes.  
However, JIP1 S59N mutation was accompanied with a Pdx-1 mutation in these 
patients, suggesting a complex genetic contribution [173].  On the other hand, 
JIP1 deficient mice did not show a diabetic phenotype [150, 174].  Thus, the role 
of JIP1 in pancreas b-cell is still unclear. 
Obesity is another stress condition that can activate JNK in many tissues 
[63].  JIP1 deficient mice were less obese compared with the WT controls after a 
high fat diet challenge [71].  This leaner phenotype was accompanied by a 
decrease in the obesity-induced JNK activation in adipose tissue, an increase in 
insulin sensitivity [174].  Moreover, mice harboring a point mutation on a JNK 
phosphorylation site of JIP1 (Mapk8ip1/Jip1Thr103Ala) that disrupts JIP1-mediated 
JNK activation also showed suppressed JNK activation in the adipose tissue 
after a high fat diet challenge [138].  Jip1Thr103Ala mutant mice were more insulin 
sensitive compared with the wild type controls [138].  In a more recent study, a 
JIP1 mutant mice with point mutations in the JNK binding domain of JIP1 
(Mapk8ip1/Jip1∆JBD) also showed a decreased JNK activation caused by 
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decreased JIP1-JNK interaction, and improved metabolic phenotype on high fat 
diet [73]. 
In consideration with the known role of JNK in metabolic regulation 
(please see section 1.2.2.), these data suggest that the improved metabolic 
phenotype observed in JIP1 deficient mice may be a consequence of a decrease 
in high fat diet-induced JNK activation.  On the other hand, given the multiple 
protein interactors of JIP1, and the complexity of the metabolic regulation, it is 
thus crucial to evaluate the tissue specific roles of JIP1 to better understand its 
role in metabolism. 
 
1.3.6 Subcellular localization of JIP1 and its role in intracellular trafficking 
JIP1 primarily exhibits a cytoplasmic localization and it is mostly absent 
from the nucleus [109, 110, 157].  Moreover, overexpression of JIP1 caused 
sequestration of its binding partners, JNK and MKK7, in the cytoplasm together 
with JIP1 [109, 132];  this finding supports the idea that JIP1 can influence the 
intracellular localization of its binding partners. 
While exogenously expressed JIP1 is detected throughout the cytoplasm, 
endogenous JIP1 in insulinoma cells was detected peripherally, adjacent to the 
cell membrane at the cell protrusions [110]. Furthermore, microscopic analysis of 
brain sections from mice and rats show that JIP1 is also localized peripherally in 
the neurons [125, 175].  However, the peripheral localization of JIP1 can 
dynamically be regulated.  For instance, while undifferentiated N1E-115 
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neuroblastoma cells show diffuse cytoplasmic JIP1 localization, as these cells 
are differentiated to neurons, JIP1 becomes concentrated at the extending 
neurites [157].  Moreover, when neurons were stimulated with an anoxic stress to 
activate JNK, peripherally localized JIP1 accumulated at the perinuclear region, 
where it co-localized with phospho-JNK [119]. These data suggest that 
depending on the functional need, JIP1 can dynamically be mobilized from one 
compartment of the cell to another. 
Kinesin and dynein motor proteins can mediate intracellular trafficking of 
their cargos [176].  Kinesin is composed of two kinesin heavy chains and two 
kinesin light chains.  In the absence of cargo binding, kinesin light chains keep 
the complex in an inactive state.  Upon activation, kinesin moves towards the 
plus end on microtubules, carrying its cargo to the cell periphery.  Dynein motor 
activity is mediated by the dynactin, which is a 23-subunit complex [177].  When 
activated, dynein motor moves towards the minus end of the microtubules, to the 
perinuclear region. 
The terminal residues at the C-terminus of JIP1 interacts with the TPR 
(Tetratricopeptide Repeat) domain of the kinesin light chain, and this interaction 
is required for the anterograde transport and peripheral localization of JIP1 in 
neurons [118-120].  A JIP1 construct that is missing JNK binding domain can still 
be localized to the axon tips when ectopically expressed in neuronal cell lines.  
This suggests that either JNK binding is not essential for kinesin mediated JIP1 
trafficking, or JIP1 dimerization with endogenous JIP proteins, which can still bind 
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JNK, may compensate for the role of the direct JIP1-JNK interaction [118, 178].  
Nevertheless, a more recent study using JIP1 knockout neurons demonstrated 
that the JNK binding of JIP1 is not essential for the role of JIP1 in kinesin-
mediated fast-velocity axonal transport [159]. 
JIP1 can also interact with proteins in the dynactin complex, such as 
ARP1 (actin related protein centractin), and p150glued [150, 160, 177, 179].  The 
interaction of JIP1 with kinesin and dynactin is implicated in the regulation of 
bidirectional trafficking of various cargos, such as Amyloid Precursor Protein 
[159, 180, 181] (APP), mitochondria [121], synaptic vesicles, and 
autophagosomes [169].  However, there is also evidence for a non-essential role 
for JIP1 in cargo trafficking.  For instance, Jip1-/-Jip2-/- double mutant mice did not 
show a major defect in the localization of mitochondria, and Synapsin-1, a 
synaptic vesicle marker, in cerebellar granule neurons (CGN) [153].  Additionally, 
JIP1 knockdown in neurons did not affect the anterograde or retrograde 
trafficking of APP in axons [182].  These studies suggest that, the role of JIP1 in 
cargo trafficking, may be essential in a specific stress condition.  Mitochondria 
and synaptic vesicle transport defect was observed in a Drosophila model [183].  
Thus, the phenotypic differences caused by JIP1 dysfunction may reflect the 
differences between Drosophila versus mammalian JIP1, or a cell and context 
specific effect.  Furthermore, JIP3-JIP1 heterodimer interaction with kinesin can 
co-operate for vesicle trafficking, and this role of JIP3 in the absence of JIP1 and 
JIP2 may compensate for the trafficking in the mammalian brain tissue [178, 
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184].  For instance, JIP1 ectopic expression can partially rescue the brain 
developmental defects in JIP3 deficient mice [185].  In conclusion, the role of 
JIP1 in the cargo transport may be highly specific to certain stress conditions in 
specific cells, thus, more research is needed to understand its regulation. 
Although JIP1 can mediate the cargo trafficking, early studies proposed 
that JIP1 binding to kinesin is not sufficient to activate the motor protein, and the 
presence of some regulatory mechanism is needed to activate kinesin once JIP1 
is loaded [186, 187].  Co-operative binding of JIP1 to kinesin light chain and Fez1 
to kinesin heavy chain was proposed as a mechanism that may activate kinesin 
[187].  However, more recent studies showed that JIP1 can interact not only with 
kinesin light chain but also with kinesin heavy chain.  The JIP1-Kinesin heavy 
chain interaction was sufficient to activate kinesin motor transport on 
microtubules [160].  It was proposed that the selectivity of JIP1 between kinesin 
and dynein complexes dependent on the phosphorylation status of JIP1.  
Concordantly, phosphorylation of JIP1 on Ser421 enhanced the anterograde 
transport of APP supporting a possible role for JNK activation on anterograde 
trafficking [160]. On the other hand, MAP Kinase Phosphatase-1 activity 
enhanced JIP1-mediated retrograde transport in neurons [169]. 
Despite this evidence for a role of JNK in anterograde trafficking by 
phosphorylating JIP1, there are studies suggesting an alternative or an additional 
role for JNK in the regulation of kinesin-mediated cargo trafficking.  For instance, 
in Drosophila, activation of the JNK pathway resulted in a decrease JIP1-kinesin 
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interactions [183].  In addition, Morfini et al. proposed that JNK can inhibit fast 
axonal transport by phosphorylating kinesin and inhibiting kinesin-microtubule 
interactions [188, 189].  These studies suggest that activated JNK may enhance 
cargo dissociation from the kinesin and microtubules. 
In cultured neurons, JIP1 is detected in a subset of neurites (cell 
protrusion) [190].  This result suggests that the peripheral localization of JIP1 in 
selected neurites require some regulatory mechanisms other than kinesin 
interaction. Reed et al. showed that JIP1 was preferentially trafficked to the 
neurites that have acetylated microtubules, concordantly a genetic mutation that 
causes acetylation of all cellular microtubules resulted in a non-preferential 
localization of JIP1 to the all neurites [190].  This data highlights the importance 
of a possible crosstalk between the scaffold proteins and the post-translational 
modifications of microtubules in selective cargo trafficking. 
Taken together, although sufficient evidence implies a role for JIP1 in the 
intracellular cargo trafficking, the regulatory mechanisms, and the relevance to 
the cellular function, especially in the context of endocrine cells is unclear. 
 
1.4 Rationale and Objectives 
1.4.1 Examining the role of JIP1-JNK pathway in beta cell function 
Although the role of JNK in the regulation of energy metabolism is 
extensively studied in many tissues with gene targeting strategies (Discussed in 
section 1.2.2.), the role of JIP1 and JNK in pancreatic b-cells is unknown.  
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Lanuza-Masdeu et al. showed that pancreas b-cell specific over-expression of 
MKK7 increased JNK activation in b-cells and resulted in decreased insulin 
secretion [191].  In addition, Kaneto et al. reported that activation of JNK in b-
cells mediates oxidative-stress induced inhibition of insulin expression [192].  
However, the conclusions in these studies regarding the role of JNK in b-cells 
were driven by indirect evidence and treatment of b-cells with non-specific JNK 
inhibitors. 
Bonny et al. suggested that JIP1 can localize to the nucleus to promote 
Glut-2 (Glucose transporter-2) expression in beta cells [126].  But, these studies 
were performed mostly in ex-vivo system.  Furthermore, the nuclear localization 
of JIP1 is questionable since many studies showed non-nuclear JIP1 localization 
in the b-cells, in addition to the neurons [109, 110, 125, 132, 157, 175]. 
Taken together, it is still a question whether JIP1-JNK pathway regulates 
insulin production and secretion in in-vivo system.  To test if there is a role for 
JIP1 in b-cell function, I have ablated the Jip1/Mapk8ip1 gene specifically in 
pancreas b-cells and evaluated the b-cell function with in-vivo and ex-vivo 
methods.  Results of these studies are presented and discussed in Chapter-2. 
 
1.4.2 Examining the role of JNK pathway in autophagy 
Autophagy is implicated in the regulation of energy metabolism and 
endocrine cell function (Discussed in section 1.1.4.).  Previous studies imply a 
role for both JIP1 and JNK in the regulation of autophagy flux.  Fu et al. 
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suggested that JIP1-mediated autophagosome trafficking from neuronal axon 
tips to the cellular soma is important for autolysosome formation and neuronal 
autophagy flux [169].  On the other hand, there are contrary results regarding the 
effect of JNK on autophagy.  Wei et al. proposed that starvation-induced 
phosphorylation of Bcl-2 by JNK is required for Beclin-1 release, and autophagy 
induction [193].  In contrary, Xu at al. reported that JNK deficient primary neurons 
show increased autophagy, and this effect was related to the differential FOXO-
dependent expression of autophagy related genes in JNK deficient cells [194]. 
These data suggest that different mechanisms may account for the 
opposing effects of JNK on the regulation of autophagy in different cell types. 
Since Bcl-2 can also be phosphorylated by other kinases [195-197], I first re-
evaluated the mechanism of the JNK-mediated autophagy in mouse embryonic 
fibroblasts (MEF).  Furthermore, I have also tested the role of JNK in autophagy 
in primary hepatocytes and kidney epithelial cells to identify possible differences 
of the cell specific JNK effect on autophagy.  Results of this study are presented 
and discussed in more detail in Chapter-3. 
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2.1 INTRODUCTION 
Insulin secretion by pancreatic b cells is essential for the normal 
physiological regulation of glycemia.  An increase in intracellular glucose induces 
insulin secretion by inhibiting potassium channels and increasing calcium flux in 
b-cells [1] (Figure 2.1.). 
 
 
Figure 2.1. Insulin secretion from pancreas beta cells in response to glucose. 
 
 
Two phases of glucose-stimulated insulin secretion have been identified 
[2].  An initial acute phase triggered by a rise in cytoplasmic calcium involves the 
rapid fusion of a readily-releasable pool of insulin granules [3].  In contrast, the 
second phase of insulin secretion is characterized by the release of a reserve 
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pool of insulin granules that generates a prolonged and low amplitude response 
that provides a major contribution to overall insulin secretion [4].  Both of these 
phases of insulin secretion by vesicle exocytosis are balanced by membrane 
endocytosis to maintain cellular homeostasis [5].  The movement of insulin 
granules to the plasma membrane where exocytosis occurs is required for 
sustained insulin secretion.  This movement appears to be mediated by a 
constrained diffusion mechanism rather than an active transport mechanism [6].  
However, remodeling of the actin and microtubule components of the 
cytoskeleton [7] may contribute to the dynamics of insulin secretion [3]. 
The microtubules in b cells form a dense multi-directional network that 
nucleates from the Golgi apparatus rather than the typical radial configuration of 
orientated microtubules nucleated at the centrosome [8].  Importantly, 
microtubules are not required for insulin secretion [8, 9].  Nevertheless, 
microtubule-mediated insulin granule transport by dynein and kinesin motor 
proteins is implicated as a regulatory mechanism for insulin secretion [10, 11].  
Recent studies have demonstrated that this microtubule-mediated insulin granule 
transport can occur within the sub-plasmalemmal space prior to secretion [12] 
and that this process may reflect local delivery / removal of insulin granules from 
docking sites for vesicle fusion on the plasma membrane [8]. 
Compelling evidence has been reported that demonstrates a role for 
microtubule-based transport in insulin secretion.  Thus, glucose stimulates 
microtubule-mediated transport of insulin granules [8, 12, 13] by a mechanism 
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that may involve both kinesin activation [13, 14] and dynamic changes in 
microtubule nucleation and stability [8].  Moreover, disruption of kinesin-1 
function strongly suppresses glucose-stimulated insulin secretion [10, 11, 13-15].   
Since microtubule-mediated insulin granule trafficking is mediated by both 
kinesin and dynein [10], disruption of one of these directional motor proteins may 
cause sequestration of insulin granules away from docking sites on the plasma 
membrane and thus suppress insulin secretion [8]. 
The trafficking function of kinesin-1 is mediated by the interaction of 
kinesin-1 with adaptor proteins that bind cargos [16].  The adapter protein that is 
relevant to the requirement of kinesin-1 for insulin secretion has not been 
identified.  Here we tested the role of the JIP1 protein, encoded by the Mapk8ip1 
gene, that is highly expressed in b cells.  JIP1 binds kinesin-1 and can function 
as a cargo adapter [17, 18].  Previous studies have implicated the human 
MAPK8IP1 gene in diabetes [19] and the murine JIP1 protein in glycemic 
regulation [20].  However, the function of JIP1 in b cells has not been defined.  
We report that JIP1 in b cells is required for normal glucose-stimulated insulin 
secretion.  This role of JIP1 depends on the interaction of JIP1 with the kinesin-1 
motor protein.  These data demonstrate that JIP1 plays a key role in the 
physiological regulation of insulin secretion by b cells. 
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2.2 RESULTS 
2.2.1 Ablation of exon2 disrupts JIP1 expression and improves glycemia 
We established mice with a floxed allele of the Mapk8ip1 gene to test the 
role of JIP1 in b cells.  The Mapk8ip1 locus in these mice includes LoxP sites that 
flank exon 2.  Cre-mediated ablation of exon 2 was confirmed by sequence 
analysis of mRNA amplified by RT-PCR (Figure 2.2.). 
 
 
 
Figure 2.2. Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), 
the targeting vector that was used for homologous recombination (HR), the 
Mapk8ip1-LacZ allele, and the conditional allele obtained using Flp recombinase 
(Left panel). RT-PCR analysis of Mapk8ip1 mRNA expression in the brain of 
JIP1WT (Mapk8ip1+/+) mice and JIP1∆Exon2 (Mapk8ip1Exon2/∆Exon2) was performed 
using oligos designed based on the sequence of exon 1 (distal) and exon 3 
(Right panel). 
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Supplementary Figure S1.  Ablation of Mapk8ip1 exon 2 disrupts JIP1 expression and improves 
glycemia.   
(A)  Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), the targeting vector that was 
used for homologous recombination (HR), the Mapk8ip1-LacZ allele, and the conditional allele obtained 
using Flp recombinase.   
(B)  RT-PCR analysis of Mapk8ip1 mRNA expression in the brain of JIP1WT (Mapk8ip1+/+) mice and 
JIP1∆Exon2 (Mapk8ip1Exon2/∆Exon2) was performed using amplimers designed based on the sequence of exon 
1 (distal) and exon 3.   
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Supplementary Figure S1.  Ablation of Mapk8ip1 exon 2 disrupts JIP1 expression and improves 
glycemia.   
(A)  Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), the targeting vector that was 
used for homologous recombination (HR), the Mapk8ip1-LacZ allele, and the conditional allele obtained 
using Flp recombinase.   
(B)  RT-PCR analysis of Mapk8ip1 mRNA expression in the brain of JIP1WT (Mapk8ip1+/+) mice and 
JIP1∆Exon2 (Mapk8ip1Exon2/∆Exon2) was performed using amplimers designed based on the sequence of exon 
1 (distal) and exon 3.   
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This analysis identified Mapk8ip1 mRNA with alternative 3’ splicing sites 
within exon 3 in both JNKWT and JIP1∆Exon2 mice.  These Mapk8ip1 mRNA 
encoded truncated JIP1 proteins with alternative in-frame translational initiation 
and stop codons (Figure 2.3.). 
 
Figure 2.3. RT-PCR analysis of Mapk8ip1 mRNA was performed using primers 
designed based on the sequence of exon 1 (distal) and exon 5. The amplicons 
were sequenced and are illustrated schematically using a cartoon of the genomic 
locus. Arrows indicate the amplified region, gray boxes represent the annotated 
exons, blue boxes represent PCR product alignments. Green circles indicate in-
frame ATG codons. Red circles indicate stop codons that are in-frame with ATG 
codons above or below each annotated sequence. 
 
Immunoblot analysis of brain lysates demonstrated the presence of full-
length and truncated JIP1 proteins in Mapk8ip1+/+ (JIP1WT) mice, loss of all JIP1 
proteins in Mapk8ip1-/- (JIP1KO) mice, and loss of only full-length JIP1 in both 
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Supplementary Figure S1.  Ablation of Mapk8ip1 exon 2 disrupts JIP1 expression and improves 
glycemia.   
(A)  Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), the targeting vector that was 
used for homologous recombination (HR), the Mapk8ip1-LacZ allele, and the conditional allele obtained 
using Flp recombinase.   
(B)  RT-PCR analysis of Mapk8ip1 mRNA expression in the brain of JIP1WT (Mapk8ip1+/+) mice and 
JIP1∆Exon2 (Mapk8ip1Exon2/∆Exon2) was performed using amplimers designed based on the sequence of exon 
1 (distal) and exon 3.   
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Mapk8ip1LoxP/LoxP Nes-Cre+/- (JIP1∆Brain) mice and germ-line JIP1∆Exon2 mice 
(Figure 2.4.). 
 
Figure 2.4. Immunoblot analysis of brain lysates prepared from JIP1WT (Nestin-
Cre+/-) mice, JIP1∆Brain (Mapk8ip1LoxP/LoxP Nestin-Cre+/-) mice, JIP1KO (Mapk8ip1-/-) 
mice, JIP1LoxP/∆Exon2 (Mapk8ip1LoxP/∆Exon2) mice, and JIP1∆Exon2 
(Mapk8ip1∆Exon2/∆Exon2) mice was performed by probing with antibodies to JIP1 and 
αTubulin. 
 
Previous studies of JIP1KO mice demonstrated that whole body JIP1 
deficiency causes improved glycemia [20].  To test whether Mapk8ip1 exon2 
ablation phenocopies the effects the Mapk8ip1 null allele, we examined germ-line 
JIP1∆exon2 mice.  These studies demonstrated that JIP1∆exon2 mice gained less fat 
mass than WT mice (Figure 2.5.). 
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Supplementary Figure S1.  Ablation of Mapk8ip1 exon 2 disrupts JIP1 expression and improves 
glycemia.   
(A)  Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), the targeting vector that was 
used for homologous recombination (HR), the Mapk8ip1-LacZ allele, and the conditional allele obtained 
using Flp recombinase.   
(B)  RT-PCR analysis of Mapk8ip1 mRNA expression in the brain of JIP1WT (Mapk8ip1+/+) mice and 
JIP1∆Exon2 (Mapk8ip1Exon2/∆Exon2) was performed using amplimers designed based on the sequence of exon 
1 (distal) and exon 3.   
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Figure 2.5. The total body mass of 8 wk old JIP1WT and JIP1∆Exon2 mice 
were fed a CD or a HFD (12 wks) was measured (upper). Fat (lower-left) and 
lean (lower-right) mass was measured by 1H-MRS. The data represent the mean 
± SEM; n=8~9; *, p<0.05 (ANOVA). 
 
These mice also exhibited improved glucose tolerance, insulin tolerance, 
and reduced fed state hyperglycemia (Figure 2.6.). 
Collectively, these data demonstrate that Mapk8ip1LoxP/LoxP (JIP1LoxP) mice 
represent a model that can be used for the examination of the tissue-specific 
effects of JIP1. 
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Figure 2.6. Glucose tolerance test (upper) and Insulin Tolerance test were 
(lower) performed on JIP1WT and JIP1∆Exon2 mice (age 20 wks) (mean ± SEM; 
n=7~9; **, p<0.01; ***, p<0.001; ****, p<0.0001; ANOVA). 
 
2.2.2 JIP1 deficiency suppresses glucose-stimulated insulin secretion 
To examine the role of JIP1 in b cells, we compared Control JIP1WT (Mip1-
CreERT+/-) mice and JIP∆ISL (Mapk8ip1LoxP/LoxP Mip1-CreERT+/-) mice with b cell-
specific ablation of Mapk8ip1 exon 2.  Genomic PCR analysis demonstrated 
ablation of exon 2 in islets of JIP∆ISL mice and immunoblot analysis confirmed 
reduced expression of JIP1 compared with Control JIP1WT mice (Figure 2.7.). 
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Figure 2.7. Genomic DNA isolated from islets of tamoxifen-treated JIP1WT 
(Mip1-CreERT+/-) and JIP1∆ISL (Mapk8ip1LoxP/LoxP Mip1-CreERT+/-) mice 
was examined by PCR to detect Mapk8ip1 exon2 ablation (left). Isolated islets 
were cultured overnight and examined by immunoblot analysis by probing with 
antibodies to JIP1, pJNK, JNK, and GAPDH (right). 
	
No significant differences in body mass, fat mass or lean mass between 
JIP1WT mice and JIP∆ISL mice were detected (Figure 2.8.).  We examined 
glucose-stimulated insulin secretion in JIP1WT and JIP∆ISL mice.  Glucose caused 
increased amounts of circulating insulin in JIP1WT mice while this effect was 
blunted in JIP∆ISL mice (Figure 2.9.).  However, no significant difference in blood 
insulin concentration between overnight-fasted JIP1WT and JIP∆ISL mice was 
detected.  These data suggest that JIP1 deficiency may reduce glucose-induced 
insulin secretion. 
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Figure 2.8. Weight gain of mice was examined (left).  Fat and lean mass of 24 
wk old mice were measured by 1H-MRS analysis.  The data presented are the 
mean ± SEM; n=10~11; p>0.05; Student’s T-test. 
 
 
Figure 2.9. Mice (age 24 wk) were fasted overnight and administered 2g/kg 
glucose by intraperitoneal injection.  Plasma insulin was measured by ELISA 
and presented as the basal fasted insulin (left) and percentage of the basal 
(right). (mean ± SEM; n=9; *, p<0.05; Student’s T-test). 
	
We performed perifusion studies using islets isolated from JIP1WT and 
JIP∆ISL mice to directly test the requirement of JIP1 for glucose-stimulated insulin 
secretion.  This analysis demonstrated that JIP1 deficiency caused decreased 
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secretion of insulin in response to glucose stimulation (Figure 2.10.).  We also 
found that JIP1 deficiency caused reduced insulin secretion in response to b cell 
depolarization with KCl (Figure 2.10.).  These secretion defects were not 
associated with decreased amounts of total intracellular insulin or Insulin and 
Slc2a2 (encodes GLUT2) mRNA (Figure 2.11.). 
 
 
Figure 2.10. Islets isolated from JIP1WT and JIP1∆ISL mice (age 24 wk) 
were examined by perifusion analysis to measure insulin secretion.  The data 
are normalized to the mean basal insulin secretion for each mouse (left).  The 
area under the curve (AUC) for first phase insulin secretion (30-34min), second 
phase insulin secretion (34-64min) and KCl stimulation (64-80min) is presented 
(right). (mean ± SEM; n=4~5 mice; *, p<0.05; Student’s T-test) 
 
To confirm a physiological role for JIP1 in b cell secretion, we examined 
the effect of re-feeding on the concentration of C-peptide in the blood of JIP1WT 
and JIP∆ISL mice.  This analysis demonstrated that the increase in circulating C-
peptide caused by re-feeding in JIP1WT mice was suppressed in JIP∆ISL mice 
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(Figure 2.12.).  These data support the conclusion that JIP1 in b cells plays an 
important role in the regulation of glucose-induced insulin secretion. 
 
Figure 2.11. The total insulin content of the islets was measured by ELISA 
(left).  Expression of Insulin-1, Insulin-2, and Slc2a2 (encodes GLUT2) mRNA by 
JIP1WT and JIP1∆ISL islets was measured by Taqman assays (right) (mean ± 
SEM; n=5 mice; p>0.05; Student’s T-test) 
 
Figure 2.12. Mice (age 24 wk) were fasted overnight and re-fed (1hr).  Plasma C-
peptide concentration was measured by ELISA and presented as % basal (mean 
± SEM; n= 8; *p<0.05; ANOVA). 
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2.2.3 JIP1 deficiency is not compensated by JIP2. 
The JIP1 and JIP2 proteins are structurally related and both proteins can 
function as cargo adapters for kinesin-1.  JIP1 and JIP2 may therefore serve 
partially redundant functions.  To test whether JIP2 might compensate for JIP1 
deficiency in b cells, we studied JIP1,2∆ISL mice with dual-deficiency of JIP1 plus 
JIP2 in b cells.  We established floxed JIP2 mice and bred these mice to obtain 
JIP1,2∆ISL mice (Figure 2.13.). 
 
	
Figure 2.13. Schematic illustration of the Mapk8ip2 genomic locus (exons 1-
12), the targeting vector that was used for homologous recombination (HR), the 
Mapk8ip2-LacZ allele, and the conditional allele obtained using Flp recombinase 
(left). Genomic DNA isolated from islets of Tamoxifen-treated JIP1,2WT (Mip1-
CreERT+/-) and JIP1,2∆ISL (Mapk8ip1LoxP/LoxP Mapk8ip2LoxP/LoxP Mip1-
CreERT+/-) mice was examined by PCR analysis (right). 
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No significant differences in body mass, fat mass, or lean mass were 
detected between Control JIP1,2WT (Mip1-CreERT+/-) mice and JIP1,2∆ISL 
(Mapk8ip1LoxP/LoxP Mapk8ip2LoxP/LoxP Mip1-CreERT+/-) mice (Figure 2.14.). 
 
 
 
Figure 2.14. JIP1WT, JIP1∆ISL, and JIP1,2∆ISL mice (age 58 wk) were 
examined by measurement of total body mass, fat mass, and lean mass 
(mean ± SEM; n=8~9; *, p<0.05; ANOVA) 
 
In contrast, reduced glucose-induced insulin secretion was detected in 
JIP1,2∆ISL mice compared with Control JIP1,2WT mice, although the circulating 
concentration of insulin in overnight fasted JIP1,2WT and JIP1,2∆ISL mice was 
similar (Figure 2.15.).  These data demonstrate that the deficiency of JIP1 or 
JIP1 plus JIP2 in b cells exhibit a similar insulin secretion defect. 
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Figure 2.15. Glucose-induced insulin secretion by JIP1,2WT and JIP1,2∆ISL 
mice (age 26 wk) was examined. Plasma insulin concentration in JIP1,2WT and 
JIP1,2∆ISL mice (age 26 wk) is presented as fasted basal (left) and percentage of 
basal (right) (mean ± SEM; n=8~9; p=0.08; ANOVA). 
	
	
2.2.4 JIP1 deficiency in beta cells causes age-dependent changes in 
glucose tolerance 
JIP1-deficient b cells secrete reduced amounts of insulin.  Consequently, 
we anticipated that JIP1∆ISL mice would exhibit glucose intolerance.  Indeed, 
comparison of mice at 4 wk post-tamoxifen treatment (age 10 wk) demonstrated 
glucose intolerance in JIP1∆ISL mice compared with JIP1WT mice (Figure 2.16.A).  
However, studies of older mice indicated that JIP1∆ISL mice subsequently 
developed improved glucose tolerance compared with JIP1WT mice (Figure 
2.16.B-E).  The JIP1∆ISL mice also exhibited an age-dependent decrease in 
fasting blood glucose concentration (Figure 2.16.F). 
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Figure 2.16. Glucose tolerance tests were performed on tamoxifen-treated (at 
age 5 wk) JIP1WT (Mip1-CreERT+/-) mice and JIP1∆ISL 
(Mapk8ip1LoxP/LoxP Mip1-CreERT+/-) mice (mean ± SEM; n=14~15; *, 
p<0.05; **, p<0.01; ***, p<0.001; Student’s T-test) (A-D).  The time after 
tamoxifen injection is indicated.  The areas under the curve (AUC) for the 
glucose tolerance tests are presented (mean ± SEM; n=14~15; *, p<0.05; **, 
p<0.01; Student’s T-test) (E).  Overnight fasting blood glucose concentration in 
aging JIP1WT and JIP1∆ISL mice was measured (mean ± SEM; n=14~15; *p<0.05; 
Student’s T-test) (F). 
 
The cause of the age-dependent improvement in glucose tolerance in JIP1∆ISL 
mice is unclear, but this observation may reflect increased peripheral insulin 
sensitivity as an age-dependent adaptation to reduced circulating concentrations 
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of insulin.  This potential mechanism is consistent with the proposed role of 
insulin to promote insulin resistance [21] and the finding that reduced insulin 
expression increases insulin sensitivity [22].  To test this prediction, we examined 
insulin-stimulated hepatic AKT activation by monitoring AKT phosphorylation on 
Thr308 and Ser473 by immunoblot analysis.  This analysis demonstrated that 
JIP1∆ISL mice exhibited significantly greater insulin-stimulated AKT activation than 
JIP1WT mice (Figure 2.17.). 
Together, these data suggest that a defect in insulin secretion may contribute 
to the reported increase in peripheral insulin sensitivity detected in whole body 
JIP1KO mice [20]. 
 
 
Figure 2.17. Insulin stimulated hepatic AKT activation in JIP1WT and 
JIP1∆ISL mice (age 24 wk) was examined by immunoblot analysis by probing 
with antibodies to pThr308AKT, pSer473AKT, AKT, and a Tubulin (left). Intensity of 
the pThr308AKT, pSer473AKT bands relative to tubulin was quantified and 
presented as bar graphs (right). (mean ± SEM; n=4; *, p<0.05; ANOVA). 
 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
- + - +- + - +
JIP1WT JIP1∆ISL
0
0.04
0.08
0.12
0.16
***
****
**
**
****
  79 
2.2.5 JIP1 deficiency causes defects in sub-cellular distribution of insulin 
vesicles in b cells 
The mechanism that accounts for the defect in insulin secretion caused by 
JIP1 deficiency in b cells is unclear.  We therefore examined the morphology of 
islets and b cells in JIP1WT and JIP∆ISL mice.  Total b cell mass is one factor that 
can limit overall insulin secretion.  However, we found that islet size and mass, 
as well as pancreas mass, were similar in JIP1WT and JIP∆ISL mice (Figure 2.18. 
and 2.19.). 
  
Figure 2.18. Representative whole slide scans of insulin (DAB/brown) and 
hematoxylin-stained pancreas sections from JIP1WT (Mip1-CreERT+/-) and 
JIP1∆ISL (Mapk8ip1LoxP/LoxP Mip1-CreERT+/-) mice (age 60 wk). (upper 
panel) Whole pancreas of the mice were dissected out and their weight were 
measured (lower right panel). The b cell mass of mice were calculated by 
multiplying the percentage insulin stained pancreas area (quantified by 
Photoshop using whole slide scans) and whole pancreas mass (lower left panel) 
(mean ± SEM; n=8; p>0.05; Student’s T-test). Scale bar=5mm 
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Figure 2.19. JIP1WT and JIP1∆ISL pancreas sections stained with an antibody to 
insulin (green) and DAPI (blue) were imaged by confocal fluorescence 
microscopy.  Scale bar=300µm. The area of 15-25 islets was quantitated for 
each mouse (age 24 wk).  The data are presented as mean ± SEM; n=7~8 mice; 
p>0.05; Student’s T-test. 
 
Transmission electron microscopy demonstrated that pancreatic islets of 
JIP1WT and JIP∆ISL mice exhibited similar overall morphology (Figure 2.20.).  
Quantitative analysis of insulin granules indicated a small, but significant 
(p<0.05), reduction in both total granule number and the number of granules 
apposed to the cell surface membrane (Figure 2.20.), although total insulin 
content was unchanged (Figure 2.10.). 
Since docked vesicles represent only part of the readily releasable pool of 
insulin granules [3], the modest decrease in granules apposed to the cell surface 
in JIP∆ISL b cells most likely does not make a major contribution to the severe 
defect in insulin secretion caused by JIP1 deficiency (Figure 2.10.). 
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Figure 2.20. Transmission electron microscope images of pancreas tissue 
from overnight-fasted mice (age 58 wks) following intraperitoneal injection (2 
min) of 2mg/kg glucose or solvent (PBS).  Highlighted regions (false color) 
indicate the cellular margins. Scale bar=2µm (E).  Total insulin vesicle number 
per µm2 cytoplasmic area (F) and docked insulin vesicles per µm cell membrane 
(G) was quantitated.  Arrowheads indicate insulin vesicles.  The data presented 
are the mean ± SEM; n=29~48 b cells; *p<0.05; **, p<0.01; ANOVA.  Scale 
bar=1µm. 
 
One possible explanation for the insulin secretion defect (Figure 2.10.) is that 
the insulin granules in JIP∆ISL b cells, unlike similar granules in JIP1WT mice, may 
not localize effectively to active sites for secretion.  This hypothesis is consistent 
with the proposal that kinesin-mediated trafficking may contribute to the 
appropriate localization of insulin granules to sites of active secretion rather than 
simple localization to the plasma membrane [8].  Indeed, studies of kinesin-1 
knockout mice, like JIP∆ISL mice, demonstrate profound defects in insulin 
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secretion in the absence of changes in insulin granule localization to the plasma 
membrane [15].  Together, these data suggest that the requirement for the JIP1 
adapter protein for insulin secretion may be related to the function of the kinesin-
1 motor protein. 
2.2.6 JIP1 binding to kinesin 1 is required for glucose-stimulated insulin 
secretion 
The primary site of JIP1 interaction with kinesin-1 is mediated by the 
COOH-terminus of JIP1 and the tetratricopeptide repeat domain of kinesin light 
chain [17, 18, 23].  Kinesin-1 light chain interactions with other regions of JIP1 
have also been detected [24] and an additional interaction of JIP1 with kinesin 
heavy chain has also been reported [25].  These secondary interactions serve to 
regulate the motor function of kinesin-1 [24, 25]. 
To test the role of the JIP1 interaction with kinesin-1, we examined the 
effect of a point mutation in the COOH terminus of JIP1 (Y705A) that disrupts the 
interaction of JIP1 with kinesin-1 in vitro.  We established Mapk8ip1Y705A/Y705A 
(JIP1Y705A) mice (Figure 2.21.). 
We demonstrated that JIP1, but not JIP1Y705A, co-immunoprecipitated with 
kinesin-1.  In contrast, both JIP1 and JIP1Y705A were found to similarly co-
immunoprecipitate with JNK (Figure 2.22.).  These data confirm that the JIP1Y705A 
mutation causes a selective defect in JIP1 interaction with kinesin-1. 
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Figure 2.21. Schematic illustration of the Mapk8ip1 genomic locus (exons 2-12), 
the targeting vector, and the Mapk8ip1Y705A allele.  The DNA and amino acid 
sequence of exon 12 showing the Y705A mutation is presented.  Homozygous 
wild-type and mutant mice were designated JIP1WT mice and JIP1Y705A mice, 
respectively. (upper panel) PCR analysis of genomic DNA identifies the wild-type 
and Mapk8ip1Y705A alleles (lower panel). 
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Figure 2.22. Immunoprecipitates (IP) were prepared from brain lysates using an 
antibody to JIP1 or non-immune antibody (Control).  The lysate and the 
immunoprecipitates were examined by immunoblot analysis using antibodies to 
kinesin heavy chain (KHC) and JIP1 (left) or JIP1 and JNK (right). 
	
 
Figure 2.23. Immunofluorescence images of cultured primary neurons stained 
for JIP1 (green), b III Tubulin (red), and DAPI (blue).  White arrowheads 
indicate growth cones located at the ends of axons.  Scale bar=20µm. 
 
We examined the localization of JIP1 in primary hippocampal neurons to 
test if this interaction defect is functionally significant.  Studies of wild-type 
neurons demonstrated that JIP1 was localized to neuronal growth cones.  In 
contrast, JIP1Y705A was localized to the soma of hippocampal neurons (Figure 
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2.23.).  These data are consistent with the hypothesis that kinesin-mediated 
trafficking drives the accumulation of JIP1 in growth cones and that, in the 
absence of kinesin-mediated trafficking, JIP1Y705A remains localized to the soma.  
These data indicate that JIP1Y705A represent a model for the analysis of JIP1-
mediated kinesin trafficking.  We compared insulin secretion by islets isolated 
from JIP1WT and JIP1Y705A mice.  Perifusion studies demonstrated that the Y705A 
mutation in JIP1 strongly suppressed glucose-induced insulin secretion by b cells 
(Figure 2.24.).  Control studies demonstrated that the total islet insulin content of 
JIP1WT and JIP1Y705A mice was similar (Figure 2.24.).  These data demonstrate 
that the JIP1 interaction with kinesin-1 is critically required for normal glucose-
induced insulin secretion. 
	
Figure 2.24. Islets isolated from JIP1WT and JIP1YA mice (age 24 wks) were 
examined by perifusion analysis to measure insulin secretion.  The data are 
normalized to total insulin content of the islets (mean ± SEM; n=4~5 mice; *, 
p<0.05; Students’ T-test) (left).  The islet perifusion data are presented as the 
area under the curve (AUC) for first phase insulin secretion (29-32 min) and 
second phase insulin secretion (32-64min) (mean ± SEM; n=4~5 mice; *, p<0.05; 
Student’s T-test) (G).  Insulin content of islets was measured by ELISA (mean ± 
SEM; n=4~5 mice; p>0.05; Student’s T-test) (H). 
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2.2.7 JNK signaling plays a regulatory role in insulin secretion 
The JIP1 adapter protein interacts with both kinesin-1 and a MAP kinase 
signaling module consisting of mixed-lineage protein kinases, MAP2K7, and JNK 
[26].  This observation suggests that JNK signaling may play a role in JIP1-
mediated cargo trafficking by kinesin-1.  Indeed, JIP1 deficiency in b cells caused 
reduced JNK activation (Figure 2.7.).  We therefore tested the role of JNK in 
insulin secretion by b cells. 
Initial studies were performed using the drug JNK-in-8 [27] that inhibits 
JNK signaling.  Perifusion experiments demonstrated that JNK-in-8 inhibited 
glucose-induced insulin secretion by b cells (Figure 2.25.).  To associate this role 
of JNK with the JIP1 adapter protein, we examined JIP1∆JBD mice with point 
mutations in the JNK binding site (replacement of Leu160-Asn161-Leu162 with 
Gly160-Arg161-Gly162) that prevent JIP1-mediated JNK activation [28].  This 
analysis demonstrated that, like the drug JNK-in-8, mutation of the JNK binding 
site on JIP1 suppresses glucose-induced insulin secretion (Figure 2.25).  
However, control studies demonstrated that the total islet insulin content of 
JIP1WT and JIP1∆JBD mice was similar (Figure 2.25.). 
These data indicate that JNK may play a regulatory role in insulin 
secretion mediated by the JIP1 adapter protein. 
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Figure 2.25. Islets isolated from JIP1WT (Mapk8ip1+/+) mice and JIP1∆JBD 
(Mapk8ip1∆JBD/∆JBD) mice (age 24 wks) were examined by perifusion 
analysis using low and high concentrations of glucose. The effects of 
treatment with JNK-in-8 or solvent (DMSO) were examined. The concentration of 
insulin in the perifusate was measured by ELISA. The data presented are 
normalized to basal insulin secretion for each mouse (mean ± SEM; n=3~4 mice; 
****, p<0.0001; ANOVA) (upper panel). Islet perifusion data are presented as the 
area under the curve (AUC) for first-phase insulin secretion (29-32min), and 
second-phase insulin secretion (32-64min) (mean ± SEM; n=3~4 mice; *, p<0.05; 
ANOVA) (lower left panel). The total amount of islet insulin was measured by 
ELISA (mean ± SEM; n=3~4; p>0.05; ANOVA) (lower right panel). 
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2.2.8 Role of JIP1 in hormone secretion 
The role of JIP1 in insulin secretion may represent a specialized function 
of JIP1 in b cells.  Alternatively, JIP1 may contribute to hormone secretion by 
other cells.  To explore this question, we examined the secretion of Thyroid-
stimulating hormone (TSH) by anterior pituitary gland thyrotrophs in response to 
Thyrotopin-releasing hormone (TRH).  TRH acts to increase cAMP in thyrotrophs 
and triggers a pulsatile pattern of TSH secretion [29].  Whole mount staining 
demonstrates that the Mapk8ip1 gene is expressed in the pituitary gland (Figure 
2.26.).  We used Cga-Cre to establish mice with JIP1 deficiency in cells that 
express the glycoprotein hormone a-subunit in the anterior pituitary gland. 
 
 
Figure 2.26. Whole mount staining of pituitary glands for LacZ expression 
was performed using X-Gal. Representative images of pituitary glands 
isolated from 24 wk old wild-type mice (WT) and mice that express LacZ 
under the control of the Mapk8ip1 promoter (Mapk8ip1-LacZ+ mice) are 
presented. 
 
JIP1-LacZ+ WT
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Comparison of JIP1WT (Cga-Cre+/-) mice and JIP1∆PIT (Mapk8ip1LoxP/LoxP 
Cga-Cre+/-) mice by PCR analysis of genomic DNA demonstrated Mapk8ip1 exon 
2 ablation in the anterior pituitary gland of JIP1∆PIT mice (Figure 2.27.).  
Immunoblot analysis confirmed that JIP1 protein expression was decreased in 
the pituitary glands of JIP1∆PIT mice compared with JIP1WT mice (Figure 2.27.). 
 
 
Figure 2.27. Genomic DNA isolated from the pituitary glands of JIP1cond 
(Mapk8ipLoxP/LoxP) mice and JIP1∆PIT (Mapk8ipLoxP/loxP Cga-Cre+/-) mice (age 24 wks) 
was examined by PCR analysis using amplimers designed based on the 
sequence of introns 1 and 2. (left). Pituitary glands from JIP1WT (CGA-Cre+/-), 
JIP1∆PIT, and JIP1KO (Mapk8ip1-/-) mice were examined by immunoblot analysis 
using antibodies to JIP1 and GAPDH (right). 
 
Analysis of blood hormones in overnight fasted mice demonstrated 
reduced amounts of circulating TSH and T4, but no change in T3, in JIP1∆PIT 
mice compared with JIP1WT mice (Figure 2.28.). 
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Figure 2.28. The concentration of circulating TSH, T4, and T3 in JIP1WT and 
JIP1∆PIT mice (age 24 wks) was measured by ELISA (mean ± SEM; n=16 
(TSH) and n=8 (T3/T4); *, p<0.05; **, p<0.01; Student’s T-test). 
 
 
Figure 2.29. Explant cultures of pituitary glands (1 h) from JIP1WT and 
JIP1∆PIT mice (age 24 wks) were treated without or with 300 nM TRH (60 
mins). The concentration of TSH in the medium was measured by ELISA 
and is presented as % of total TSH (mean ± SEM; n=4~5; **, p<0.01; ***, 
p<0.001; ****, p<0.0001; ANOVA) (left). Pituitary gland expression of 
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Supplementary Figure S4.  JIP1 promotes TRH-stimulated TSH secretion from thyrotrophs in the 
anterior pituitary gland.   
(A)  Whole mount staining of pituitary glands for LacZ expression was performed using X-Gal.  
Representative images of pituitary glands isolated from 24 wk old wild-type mice (WT) and mice that 
express LacZ under the control of the Mapk8ip1 promoter (Mapk8ip1-LacZ+ mice) are presented.   
(B) Genomic DNA isolated from the pituitary glands of JIP1cond (Mapk8ipLoxP/LoxP) mice and JIP1∆PIT 
(Mapk8ipLoxP/loxP Cga-Cre+/-) mice (age 24 wks) was examined by PCR analysis using amplimers designed 
based on the sequence of introns 1 and 2.   
(C)  Pituitary glands from JIP1WT (CGA-Cre+/-), JIP1∆PIT, and JIP1KO (Mapk8ip1-/-) mice were examined by 
immunoblot analysis using antibodies to JIP1 and GAPDH.   
(D)  The concentration of circulating TSH, T4, and T3 in JIP1WT and JIP1∆PIT mice (age 24 wks) was 
measured by ELISA (mean ± SEM; n=16 (TSH) and n=8 (T3/T4); *, p<0.05; **, p<0.01; Student’s T-test).   
(E)  Explant cultures of pituitary glands (1 h) from JIP1WT and JIP1∆PIT mice (age 24 wks) were treated 
without or with 300 nM TRH (60 mins).  The concentration of TSH in the medium was measured by 
ELISA and is presented as % of total TSH (mean ± SEM; n=4~5; **, p<0.01; ***, p<0.001; ****, p<0.0001; 
ANOVA).   
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(C)  Pituitary glands from JIP1WT (CGA-Cre+/-), JIP1∆PIT, and JIP1KO (Mapk8ip1-/-) mice were examined by 
immunoblot analysis using antibodies to JIP1 and GAPDH.   
(D)  The concentration of circulating TSH, T4, and T3 in JIP1WT and JIP1∆PIT mice (age 24 wks) was 
measured by ELISA (mean ± SEM; n=16 (TSH) and n=8 (T3/T4); *, p<0.05; **, p<0.01; Student’s T-test).   
(E)  Explant cultures of pituitary glands (1 h) from JIP1WT and JIP1∆PIT mice (age 24 wks) were treated 
without or with 300 nM TRH (60 mins).  The concentration of TSH in the medium was measured by 
ELISA and is presented as % of total TSH (mean ± SEM; n=4~5; **, p<0.01; ***, p<0.001; ****, p<0.0001; 
ANOVA).   
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Tsh  mRNA was measured by qRT-PCR analysis (mean ± SEM; n=7~8, *, 
p>0.05; Student’s T-test) (right). 
Since TSH secretion in vivo is positively regulated by TRH and negatively 
regulated by T4/3, we examined TSH secretion using pituitary gland explants in 
vitro.  These studies demonstrated that JIP1 deficiency caused reduced TRH-
stimulated secretion of TSH (Figure 2.29.).  This defect in secretion was not 
associated with a change in the expression of Tshb mRNA (Figure 2.29.). 
To test the role of the interaction of JIP1 with kinesin-1 in thyrotrophs, we 
examined TRH-induced TSH secretion from the anterior pituitary glands of 
JIP1WT and JIP1YA mice.  This analysis demonstrated that the Y705A mutation in 
JIP1 strongly suppressed TRH-induced TSH secretion (Figure 2.30.).  Thus, like 
insulin secretion from b cells, TSH secretion from thyrotrophs requires the 
interaction of JIP1 with kinesin-1. 
             
Figure 2.30. Explant cultures of pituitary glands were treated with TRH (30 
min) and the concentration of TSH in the medium was measured by ELISA.  
Secreted TSH is presented as the percentage of total pituitary TSH content 
(mean ± SEM; n=4; *, p<0.05; ANOVA). 
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2.3 DISCUSSION 
Our data demonstrate that the kinesin-1 adapter protein JIP1 plays a key role 
in hormone secretion, including the release of insulin from b cells.  JIP1 
deficiency in b cells reduces glucose-induced insulin secretion (Figure 1).  
Importantly, a mutation in JIP1 (Y705A) that prevents the interaction of JIP1 with 
kinesin-1 suppresses glucose-induced insulin secretion (Figure 4).  Similarly, 
disruption of kinesin-1 function in b cells also causes reduced glucose-induced 
insulin secretion [10, 11, 13-15].  Together, these data demonstrate that the JIP1 
adapter protein is important for kinesin-regulated insulin secretion.  This function 
may be mediated by a role for kinesin-mediated trafficking to increase the dwell 
time of insulin granules at sites of membrane fusion at the cell surface by 
opposing dynein-mediated trafficking [8]. 
A goal for future studies will be to examine regulatory mechanisms mediated 
by JIP1 that influence insulin secretion by directly visualizing insulin granule 
dynamics.  One example of a potential regulatory mechanism is the JNK pathway 
that is tethered as a signaling module to JIP1 [30].  Genetic analysis indicates 
that JNK potently stimulates kinesin-mediated cargo transport [31] and 
biochemical studies demonstrate that this role of JNK is mediated, in part, by 
kinesin-1 phosphorylation [32, 33].  This established knowledge is consistent with 
the observations that JIP1 deficiency in b cells causes reduced JNK activation 
(Figure 1B), that pharmacological inhibition of JNK causes reduced insulin 
secretion (Figure S3), and that mutation of the JNK binding site on JIP1 
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suppresses insulin secretion (Figure S3).  Together, these data suggest that local 
control of JNK signaling by JIP1 that targets the kinesin-1 motor protein may 
represent a key mechanism for the physiological control of insulin secretion. 
 
2.4 METHODS 
2.4.1 Animal Models 
2.4.1.1 Mouse husbandry 
The mice were housed with ad libitum access to food and water with a 
12:12-hr dark-light cycle, in a specific pathogen-free facility accredited by the 
American Association for Laboratory Animal Care.  The Institutional Animal Care 
and Use Committee of the University of Massachusetts approved all studies 
using animals.  All studies were performed using C57BL/6J background, age-
matched, male mice.  Littermate mice were randomly assigned to groups. 
Mice (aged 8 wk) were fed a chow diet (Iso Pro 3000, Purina) or high fat 
diet (S3282, Bioserve).  Body mass was measured with a scale.  Fat mass and 
lean mass were non-invasively measured using 1H-MRS (Echo Medical 
Systems). 
2.4.1.2 Previously published mouse models 
We have previously described Mapk8ip1-/- (JIP1 knockout) mice [17] and 
JIP1∆JBD mice [28].  C57BL/6J mice (stock# 000664), B6.Cg-Tg(Ins1-
cre/ERT)1Lphi/J (Mip1-CreERT) mice (stock# 024709) [34], B6;SJL-Tg(Cga-
cre)3Sac/J (Cga-Cre) mice (stock#004426) [35], B6.Cg-Tg(Nes-cre)1Kln/J 
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(Nes-Cre) mice (stock# 003771) [36], B6.Cg-Tg(Syn1-cre)671Jxm/J (Syn1-Cre) 
mice (stock# 003966) [37], and 129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP)Dym/J 
(FLPeR) mice (stock# 003946) [38] were obtained from The Jackson 
Laboratory. 
2.4.1.3 Establishment of Mapk8ip1Y705A/Y705A mice 
Mice with the point mutation Tyr705Ala in JIP1 were constructed by 
homologous recombination in embryonic stem (ES) cells using standard 
methods.  Briefly, a targeting vector was constructed (Figure 4A).  This targeting 
vector was designed to introduce point mutations in exon 12 of the Mapk8ip1 
gene that create the Tyr705Ala mutation and, the loss of an EcoRV restriction 
site (Figure 4A).  The targeting vector was also designed to introduce a floxed 
NeoR cassette in intron 7 (Figure 4A).  TC1 embryonic stem cells (strain 129svev) 
were electroporated with this vector and selected with 200 µg/ml G418 (Thermo 
Fisher Cat#10131035) and 2 µM ganciclovir (Syntex).  ES cell clones with the 
floxed NeoR cassette correctly inserted in intron 7 were identified by Southern 
blot analysis.  ES cells were injected into C57BL/6J blastocysts to create 
chimeric mice that were bred to obtain germ-line transmission of the targeted 
Mapk8ip1 allele.  The floxed NeoR cassette was excised using Cre recombinase.  
These mice were backcrossed to the C57BL/6J strain. 
2.4.1.4 Establishment of Mapk8ip1LoxP/LoxP and Mapk8ip2LoxP/LoxP mice 
A Frt-LacZ-LoxP-NeoR-Frt-LoxP cassette was inserted by homolgous 
recombination in intron 1 and a LoxP site was inserted into intron 2 of the 
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Mapk8ip1 gene (Figure S1A) and Mapk8ip2 gene (Figure S2A).  We used 
JM8A3.N1 ES cells (strain C57BL/6N-A/a; Mapk8ip1tm1a(EUCOMM)Wtsi) and 
JM8A3.N1 ES cells (strain C57BL/6N; Mapk8ip2tm1a(EUCOMM)Wtsi) to create 
chimeric mice that were bred to obtain germ-line transmission of the mutated 
Mapk8ip1-LacZ and Mapk8ip2-LacZ alleles using standard procedures.  The Frt-
LacZ-LoxP-NeoR-Frt cassette was excised by crossing with FLPeR mice to 
obtain mice with the Mapk8ip1LoxP and Mapk8ip2LoxP alleles.  These mice were 
backcrossed to the C57BL/6J strain. 
2.4.1.5 Establishment of Mapk8ip1∆Exon2/∆Exon2 mice 
Mapk8ip1LoxP/LoxP mice were bred with Synapsin1-Cre+/- mice to obtain 
male Mapk8ip1+/LoxP Synapsin1-Cre+/- mice that were bred with female C57BL/6J 
mice.  Cre expression in the male germ-line resulted in the generation of 
Mapk8ip1+/∆Exon2 mice that were bred to obtain Mapk8ip1∆Exon2/∆Exon2 mice. 
2.4.1.6 Establishment of tissue-specific JIP-deficient mice 
We bred floxed mice and Cre+/- mice to generate mice with the following 
genotypes for analysis:  Control and JIP1∆ISL mice (Mip1- CreERT +/- and 
Mapk8ip1LoxP/LoxP Mip1- CreERT +/- mice); Control and JIP1,2∆ISL mice (Mip1- 
CreERT +/- and Mapk8ip1LoxP/LoxP Mapk8ip2LoxP/LoxP Mip1- CreERT +/- mice); Control 
and JIP1∆PIT mice (Cga-Cre+/- and Mapk8ip1LoxP/LoxP Cga-Cre+/- mice); and Control 
and JIP1∆Brain mice (Nestin-Cre+/- and Mapk8ip1LoxP/LoxP Nestin-Cre+/- mice).  
CreERT mice (age 5 wks) were injected with 1.5mg tamoxifen (Millipore Sigma 
Cat#T5648-16) in 100µl sunflower seed oil every other day for 8 days (4 
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injections). 
2.4.1.7 Genotype analysis 
Genomic DNA was isolated from mouse tissues (brain, islets, and pituitary 
gland) using the DNeasy Blood and Tissue Kit (Qiagen cat#69506).  PCR 
analysis of genomic DNA using amplimers 5’- TCCCAGGTCTCCTTCACTGT-3’ 
and 5’-CGGCTCTATTGGAGAGATGC-3’ detected the Mapk8ip1+ (202bp) and 
Mapk8ip1LoxP (366bp) alleles.  Amplimers 5’-
TGTAGTTGAAGAGATGACACCAAGA-3’ and 5’-
CTGAGAGGCCCTTCTCTTAACTCT-3’ detected the Mapk8ip1+ (926bp), 
Mapk8ip1LoxP (1,137bp), and Mapk8ip1∆exon2 (335bp) alleles.  PCR analysis using 
primers 5’-GACGGCAGAGAGTGAAATC-3’, 5’-ATACCTTGAACCAACGGGG-3’, 
and 5’-GGCATTTCCTCAAAACAAGC-3’ detected the Mapk8ip2+ (188bp), 
Mapk8ip2LoxP (392bp), and Mapk8ip2∆exon2 (325bp) alleles.  Amplimers 5’-
ACACACACCCCAGGTCTTAG-3’ and 5’-TCAGCTTTGACGCCTATCTTGAC-3’ 
detected the Mapk8ip1+ (550bp) and Mapk8ip1Y705A alleles (680bp).  Methods for 
genotyping JIP1 knockout mice [17], JIP1∆JBD mice [28], Cre mice [36], and Flp 
mice [38] have been reported previously. 
2.4.1.8 Sequencing of Mapk8ip1 mRNA 
Brain RNA from WT and JIP1∆Exon2 mice was amplified by RT-PCR using 
primers designed based on the sequence of distal exon 1 (5’-
CATTCCTGGGACTGCACAT-3’) or proximal exon 1 (5’-
AGCTGGTTGGAGGATCAGTG-3’) together with exon 5 (5’-
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CACATCTGCCTGGTAGTGGA-3’) (Figure S1C).  Amplicons were purified 
using 1.8X AMPure XP reagent (Fisher Scientific Cat#A63880).  The purified 
amplicons were incubated (50 µL) with 1mM dATP (Thermo Fisher Cat#R0141) 
and 15U Klenow 3′->5′ exo-  (New England Biolabs Cat#M0212) in 1X NEB 
buffer 2.1 (New England Biolabs Cat#B7202) at 37°C (30 mins).  The A-tailed 
amplicons were purified using 1.8X AMPure XP reagents and then incubated (50 
µL) at 25°C (2 h) with 25U T4 ligase (Thermo Fisher, Cat#15224041) plus 20nM 
indexed adapters (TrueSeq RNA Single Indexes Set-A (Cat# 20020492) and Set-
B (Cat# 20020493)) in 1X T4 ligase buffer (New England Biolabs), followed by 
1.8X AMPure XP purification.  The libraries were mixed (4:1) with a PhiX Control 
v3 library (Illumina Cat#FC-110-3001) and sequenced using an Illumina MiSeq 
(300bp paired-end reads, 300,000 mean reads per library).  Reads were aligned 
to the mouse reference genome mm10 using Tophat2 [39] and visualized using 
the Integrative Genomics Viewer [40]. 
2.4.1.9 Blood Analysis 
Blood glucose was measured with an Ascensia Breeze 2 glucometer 
(Bayer).  Multiplexed ELISA (Luminex 200 machine, Millipore Sigma) was used 
to measure the concentration of insulin with the Mouse Adipokine Magnetic Bead 
Panel (Millipore Sigma Cat#MADKMAG-71K), C-Peptide was measured with the 
Mouse Metabolic Magnetic Bead Panel (Millipore Sigma Cat#MMHMAG-44K), 
and TSH / GH were measured with the Mouse Pituitary Magnetic Bead Panel 
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(Millipore Sigma Cat#MPTMAG-49K-03).  ELISA was used to measure the 
concentration of T4 (Calbiotech Cat#T4224T) and T3 (Calbiotech Cat#T3225T). 
2.4.1.10 Glucose Stimulated Insulin Secretion in vivo 
Mice were starved overnight (16 h) and injected with 2g/kg glucose.  Blood 
was collected at 0, 5 and 15 mins post-injection.  The concentration of insulin 
was measured by multiplexed ELISA. 
2.4.1.11 Glucose Tolerance Test 
Glucose tolerance tests were performed using mice starved overnight (16 
h) and intraperitoneally injected with 2g/kg glucose.  However, glucose tolerance 
studies using old mice (≥60 wks) were performed using 1.5 g/kg glucose and 
HFD studies were performed using 1.0 g/kg glucose. 
2.4.1.12 Insulin Stimulated AKT Phosphorylation 
Mice were starved overnight and intraperitoneally injected with 1U/kg 
insulin or solvent (phosphate-buffered saline).  The mice were euthanized at 15 
mins post-injection and liver tissue was flash-frozen in liquid nitrogen.  Tissues 
lysates were examined by immunoblot analysis. 
2.4.1.13 Immunoprecipitation 
Extracts of murine cerebral cortex were prepared in Triton lysis buffer 
[20 mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM 
EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, and 10 μg/mL of aprotinin plus leupeptin].  
Immunoprecipitation was performed using a rabbit antibody to JIP1 [41], a rabbit 
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antibody to JNK (Santa Cruz; cat#sc474), and non-immune rabbit IgG (Millipore 
Sigma cat#I5006) pre-bound to protein A Sepharose (Millipore Sigma 
cat#P3391).  The immunoprecipitates were examined by immunoblot analysis. 
2.4.1.14 Immunoblot Analysis 
Tissue extracts from brain, isolated islets, and pituitary gland were 
prepared using Triton lysis buffer. Extracts (20–50 μg protein) were examined by 
immunoblot analysis by probing with antibodies to JIP1 (Fisher Scientific 
Cat#BDB611890), pJNK1/2 (Cell Signaling Cat#4668), JNK1/2 (Fisher Scientific 
Cat#BDB554285), AKT (Cell Signaling Cat#9272), pAKTT308 (Cell Signaling 
Cat#5106), pAKTS473 (Cell Signaling Cat#9271), Kinesin Heavy Chain (Millipore 
Cat#MAB1614), GAPDH (Santa Cruz Cat#sc-25778), and aTubulin (Sigma-
Aldrich Cat#T5168). Immunocomplexes were detected by enhanced 
chemiluminescence (New England Nuclear) or by fluorescence using anti-mouse 
and anti-rabbit secondary IRDye antibodies (LI-COR Biosciences Cat#925-68070 
and Cat#925-32211) and quantitated using the LI-COR Imaging system. 
2.4.1.15 Primary Islet Isolation and Perifusion Analysis 
Islets were isolated by collagenase digestion of pancreas [42] and used 
for perifusion studies [43] using methods described previously.  Islets were 
cultured overnight in CMRL media (Thermo Fisher Cat#11530037) with 5.5 mM 
glucose supplemented with 10% FBS (Atlanta Biologicals Cat#S11150H), 1x 
Pen/Strep/Glutamine (Thermo Fisher Cat# 10378016) and 1x MEM Non 
Essential amino acids (Thermo Fisher Cat# 11140-076).  Similar-sized islets from 
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each mouse preparation were hand-picked and 25 islets were examined using a 
Biorep Technologies (Miami, FL) perifusion system.  Islets were perifused with 
Kreb’s buffer [115mM NaCl, 5mM KCl, 24mM NaHCO3, 1mM MgCl2, 2.2mM 
CaCl2 at pH 7.4] supplemented with 0.17% bovine serum albumin and 2.5 mM 
glucose (90 min), followed by 20 mM glucose (35 min), 20 mM KCl plus 3mM 
glucose (10 min) and finally 2.5 mM glucose (15 min).  Medium was collected at 
a flow rate 100 µl/min to assess insulin secretion.  Insulin concentration was 
measured using an Insulin ELISA kit (Alpco cat#80-INSMSU-E01).  The islets 
were collected at the end of the study and placed in acidified ethanol overnight to 
determine total insulin levels. 
2.4.1.16 Gene Expression Analysis 
Isolated islets and tissues were used to prepare RNA using an RNAeasy 
mini kit (Qiagen Cat#74106).  0.5-1µg RNA was converted into cDNA using the 
high-capacity cDNA reverse transcription kit (Thermo Fisher Cat#4368813).  
TaqMan assays were used to quantify Ins1 (Assay ID: Mm01259683-g1), Ins2 
(Assay ID: Mm00731595-gH), Slc2a2 (Assay ID: Mm00446229_m1), and Tshb 
(Assay ID: Mm03990915-g1) genes using a Quantstudio PCR machine (Thermo 
Fisher).  The relative mRNA expression was normalized by measurement of the 
amount of 18S RNA in each sample using Taqman assays (Thermo Fisher 
Cat#4308329). 
Mapk8ip1 mRNA from JIP1WT and JIP1∆Exon2 mice was examined by RT-PCR 
assays of total RNA using primers designed based on the sequence of distal 
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exon 1 (5’-CATTCCTGGGACTGCACAT-3’) and exon 3 (5’-
CTCTTGGGTCGGTAGGTGTC-3’) (Figure S1B). 
2.4.1.17 Measurement of b cell mass 
We measured islet area within pancreas sections using procedures we 
have reported previously [44].  Briefly, pancreas tissue was fixed in 10% formalin 
(24 h), dehydrated, and embedded in paraffin. Sections (7μm) were cut and 
stained using Insulin antibody (Dako Cat#A0564).  Immune complexes were 
detected using peroxidase-conjugated AffiniPure donkey anti-guinea pig antibody 
(Jackson ImmununoResearch Cat#706-035-148) and the staining was developed 
with 3,3'diaminobenzidine (Vector Laboratories, DAB peroxidase substrate kit, 
Cat#SK-4100).  The slides were counter-stained with hematoxylin (Fisher 
Cat#50-823-93) and scanned (Nikon CoolScan).  The images were color-
separated (red/blue) and converted to gray scale and thresholded using Adobe 
Photoshop software (Adobe San Jose, CA).  Pancreas and b cell areas were 
quantified using Image J (National Institutes of Health, Bethesda, MD).  The b 
cell mass was calculated as pancreas mass x (b cell area / pancreas area).  The 
quantitation of b cell mass was performed in a blinded manner with respect to 
genotype identity. 
2.4.1.18 Immunofluorescence Staining of Insulin 
Immunofluorescence staining of insulin was performed using 7µm thick 
paraffin embedded pancreas sections stained with an antibody to Insulin (DAKO 
Cat#A0564) plus a goat anti-guinea pig Alexa-Fluor-488 antibody (Invitrogen 
  102 
Cat#A-11073).  DNA was detected by staining with DAPI (Life Technologies).  
Fluorescence was visualized using a Leica TCS SP2 confocal microscope 
equipped with a 405-nm diode laser.  Quantitation of islet size was performed in 
a blinded manner with respect to genotype identity. 
2.4.1.19 TRH-induced TSH secretion 
Pituitary gland explant cultures have been previously reported [45]. Briefly, 
dissected pituitary glands were cultured in 1 ml DMEM (Thermo Fisher 
Cat#11960-051) supplemented with 10% bovine growth serum (Fisher Scientific 
Cat#SH3054103), 1x L-glutamine (Thermo Fisher cat#25030081), 1x 
Penicillin/Streptomycin (Thermo Fisher cat#15140122), and 1x protease inhibitor 
cocktail (Millipore Sigma Cat#P1860).  The glands were cultured (1h) and then 
transferred to fresh culture medium (1 ml) supplemented without or with 300nM 
TRH (Millipore Sigma Cat#P1319).  Medium (50 µL) was collected at 30 and 60 
mins.  The pituitary glands were then homogenized in PBS supplemented with 1x 
protease inhibitor cocktail. 
2.4.1.20 X-Gal histochemistry 
Whole pituitary glands were dissected and fixed in fresh 4% 
paraformaldehyde (1h).  The glands were incubated (3 times, 30 min, 25°C) in 
Rinse Buffer (100 mM sodium phosphate (pH 7.3), 2 mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% NP-40).  The glands were then stained overnight (4°C) in 
Rinse Buffer supplemented with 5 mM potassium ferricyanide, 5 mM potassium 
  103 
ferrocyanide, 1 mg/ml X-gal).  The glands were post-fixed overnight in 
10%formalin (4°C). 
2.4.1.21 Electron Microscopy 
The methods used for sample preparation and electron microscopy were 
described previously [46] by the UMASS Electron Microscopy Core.  Briefly, mice 
were starved overnight and injected with 2gr/kg glucose or solvent (phosphate-
buffered saline). The mice were euthanized at 2 min post-injection.  The 
pancreas was immediately dissected, cut in 1-2mm3 cubes, and immersed in 
fixation solution (2.5% glutaraldehyde in 100 mM cacodylate pH 7.2).  The tissue 
was fixed overnight, rinsed in cacodylate buffer and then incubated with 1% 
osmium tetroxide (1 hr, 25°C).  The samples were rinsed with cacodylate buffer 
and then dehydrated through a graded ethanol series (20% increments) before 
two changes in 100% ethanol.  The samples were then infiltrated with two 
changes of 100% propylene oxide and then with 50%/50% propylene oxide / SPI-
Pon 812 resin.  On the next day, three changes of fresh 100% SPI-Pon 812 resin 
were performed before the samples were polymerized at 68°C in plastic 
capsules.  The samples were then sectioned (1 μm) and stained with toluidine 
blue to locate the islets.  The tissue was then re-trimmed with islets in the center 
and thin sections (approx. 70 nm) were prepared and placed on copper support 
grids and contrasted with lead citrate and uranyl acetate.  The sections were 
examined using FEI Tecani 12 BT microscope with 80Kv accelerating voltage, 
and images were captured using a Gatan TEM CCD camera.  The images were 
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false-colored to highlight individual cells using Adobe Photoshop software.  
Quantitation of insulin granules was performed in a blinded manner with respect 
to genotype identity. 
2.4.1.22 Primary Neuron Assays 
Hippocampal neurons were cultured from E17.5 mouse embryos [17].  
The neurons were maintained in serum-free Neurobasal medium (Thermo Fisher 
Cat#21103049) with the addition of B27 supplement (Thermo Fisher 
cat#17504044).  The neurons were fixed by incubation with 4% 
paraformaldehyde in PBS.  After permeabilization with 0.1% Triton X-100, the 
cells were incubated in blocking buffer (1% BSA, 2% normal goat serum in 
phosphate-buffered saline) for 1 h, and then incubated in blocking buffer with 
primary antibodies to JIP1 (Santa Cruz Biotechnology Cat#sc-15353) and b3-
Tubulin (Biolegend Cat#TUBB3).  The primary antibodies were detected by 
incubation with anti-mouse and anti-rabbit Ig conjugated to Alexa Fluor 488 or 
633 (Thermo Fisher Cat#A-11029 and Thermo Fisher Cat# A-21071) DNA was 
detected by staining with DAPI (Thermo Fisher Cat#D1306)). Fluorescence was 
visualized using a Leica TCS SP2 confocal microscope equipped with a 405-nm 
diode laser. 
2.4.1.23 Quantification and statistical analysis 
Immunoblots were quantitated using Image Studio software 
(https://www.licor.com/bio/products/software/image_studio/) (LICOR-
Biosciences).  Images were quantitated using Image J64 software 
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(https://imagej.nih.gov/ij/) (National Institutes of Health).  Differences between 
two group were examined for statistical significance using the two-tailed 
Student’s test with Microsoft Excel software (https://products.office.com/en-
us/excel).  Multiple comparisons were examined by ANOVA using GraphPad 
Prism software (http://www.graphpad.com/scientific-software/prism).  Statistical 
details are presented in the Figure legends. 
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CHAPTER 3: Role of the cJun NH2-Terminal Kinase (JNK) signaling 
pathway in starvation-induced autophagy 
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3.1 INTRODUCTION 
Autophagy is a cellular mechanism that enables recycling of cytoplasmic 
content and plays an important role in cellular homeostasis [1, 2].  Autophagy is 
initiated with the formation of the phagophore, a double membrane structure that 
surrounds a portion of cytoplasm [3].  These structures progress to the 
development of autophagosomes that fuse with lysosomes to form autophago-
lysosomes that release nutrients to the cytoplasm(Figure 3.1.) [3].     
       
Figure 3.1. Cartoon represents the recycle of cytoplasmic components by 
autophagy. Previously suggested role of JNK in autophagy pathway is 
highlighted by red, where JNK has an inhibitory role on autophagy through 
mTOR, and green, where JNK has an inducer role on autophagy through Beclin-
1. 
? 
? 
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A major regulator of autophagy is established to be the Mechanistic Target of 
Rapamycin (mTOR) pathway that can sense cellular energy and amino acid 
levels [4].  TORC1 is activated when cells are in a nutrient rich environment, 
which leads to inhibition of autophagy [4].  However, suppression of TORC1 
activity in response to low energy balance or amino acid starvation causes 
increased autophagy [4]. 
It was recently reported that MAPK8/JNK1 (but not MAPK9/JNK2) is required 
for the induction of autophagy by starvation [5].  This mechanism of MAPK8 
signaling is mediated by BCL2 phosphorylation (on Thr-69, Ser-70, and Ser-87) 
that disrupts BCL2/BECN1 interactions and initiates BECN1-dependent 
autophagy [5].  Subsequent studies have provided strong support for this role of 
MAPK8 in autophagy [6-19], although contributing roles for MAPK9 [20-23] and 
alternative potential functions of MAPK8 related to autophagy have also been 
reported [24-29]. 
The MAPK8-promoted autophagy pathway raises several questions.  First, 
what is the mechanistic relationship between the MAPK8 and mTOR pathways in 
the regulation of autophagy by starvation?  Second, since MAPK8 exhibits 
functional redundancy as a BCL2 kinase [20, 30-34], what mechanism accounts 
for the requirement of MAPK8 for starvation-induced autophagy?  The purpose of 
this study was to examine these two questions in the context of starvation-
induced autophagy.  We show that the role of MAPK8/9 in autophagy may be 
context-dependent and substantially more complex than previously considered. 
  114 
3.2 Results 
3.2.1 mTOR-regulated autophagy does not require MAPK8/9 (JNK) 
It is established that mTOR is a master regulator of starvation-induced 
autophagy [4].  The requirement of MAPK8 for starvation-induced autophagy [5] 
may therefore reflect a role for MAPK8 upstream or down-stream of mTOR.  
Indeed, previous studies have demonstrated that MAPK8/9 can be activated in 
response to TORC1 signaling [35] and that TORC1 activation can require 
MAPK8/9 signaling [28].  Alternatively, MAPK8/9 and TORC1 may function in 
parallel pathways that control autophagy. 
To test whether MAPK8/9 plays a role in autophagy induction downstream 
of mTOR, we examined the effect of Torin1, a small molecule inhibitor of mTOR.  
Control studies demonstrated that Torin1 prevented the phosphorylation of the 
mTOR substrate Thr-389 RPS6KB1/p70-S6K1 in both wild-type (WT) and 
Mapk8-/- Mapk9-/- (JNK∆1,2) immortalized MEF (Figure 3.2.). 
 
Figure 3.2. The amount of RPS6KB1 (p70), pThr-389 RPS6KB1 (p-p70), and a-
Tubulin in WT and JNK∆1, 2 immortalized MEF after incubation without or with 
250nM Torin1 (2 or 4 h) was examined by immunoblot analysis. 
	
	
Torin1- -
p70
P-p70
Tubulin
JNK∆1,2WT
2h 4h2h4h - -
JNK∆1,2WT
2h 4h2h4h - -
JNK∆1,2WT
2h 4h2h4h
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To assess the effect of Torin1 on autophagy, we initially examined the 
formation of MAP1LC3B /LC3B puncta in the cytoplasm by fluorescence 
microscopy.  We found that Torin1 caused similar MAP1LC3B puncta in both WT 
and JNK∆1,2 immortalized MEF (Figure 3.3.). 
   
Figure 3.3. WT and JNK∆1, 2 immortalized MEF were transduced with a lentivirus 
vector that expresses eGFP- MAP1LC3B (eGFP-LC3B).  Puncta formation 
following incubation of the cells with 250 nM Torin1 (2h and 4h) was examined by 
fluorescence microcopy.  Scale bar = 30 µm. 
 
This observation suggested that MAPK8/9 deficiency caused no major 
change in autophagy as a result of mTOR inhibition.  This conclusion was 
confirmed by measurement of autophagic flux by monitoring the formation of 
MAP1LC3B-II in response to mTOR inhibition in the presence of a lysosomal 
inhibitor [36] (Figure 3.4.) and reduced accumulation of the autophagic substrate 
SQSTM1/p62 (Figure 3.5.). 
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Figure 3.4. MAP1LC3B (LC3B) and GAPDH expression by WT and JNK∆1, 2 
immortalized MEF after incubation (2 h) without or with 250 nM Torin1 in the 
absence or presence of 25 µM chloroquine (CQ) was examined by immunoblot 
analysis.  The LC3B-II/GAPDH ratios were normalized to the mean of WT control 
condition (first lane).  The data presented represent the mean ± SEM; n=3 
independent experiments; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.  
Two-way ANOVA was used for the analysis of LC3B-II expression and Student’s 
T test is used for the flux analysis. 
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Figure 3.5. The amount of SQSTM1 (p62) and a-Tubulin in WT and JNK∆1, 2 
immortalized MEF after incubation with 250 nM Torin1 (2 or 4 h) was examined 
by immunoblot analysis.  The p62/Tubulin ratio was quantitated and normalized 
to p62 expression in WT cells treated without Torin1 (mean ± SEM; n=3 
independent experiments; **, p<0.01 (two-way ANOVA). 
 
Torin1 is an active site-directed inhibitor of mTOR and therefore inhibits 
both mTOR complexes TORC1 and TORC2 [37].  To test the role of TORC1, we 
used low dose Rapamycin to selectively block TORC1 [37].  Control studies 
- -
WT
Tubulin
p62
JNK∆1,2
Torin1
0.5
0
1
1.5
2
**
**2.5 **
2h 4h- 2h 4h- 2h 4h- 2h 4h- Torin1
p62
Tubulin
WT WTJNK∆1,2 JNK∆1,2
  118 
demonstrated that Rapamycin inhibited phosphorylation of the TORC1 substrate 
Thr-389 RPS6KB1, but not the TORC2 substrate Ser-473 AKT (Figure 3.6.). 
 
 
Figure 3.6. RPS6KB1 (p70), pThr-389 RPS6KB1 (P-p70), AKT, pThr-308 AKT, 
pSer-473 AKT, and GAPDH expression by WT and JNK∆1, 2 immortalized MEF 
after incubation (2 h) without or with 200 nM Rapamycin was examined by 
immunoblot analysis. 
	
We found that treatment of WT and JNK∆1,2 immortalized MEF with rapamycin 
caused a similar increase in autophagic flux that was measured by monitoring 
the accumulation of MAP1LC3B-II in the presence of a lysosomal inhibitor [36] 
(Figure 3.7.).	
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Figure 3.7. MAP1LC3B (LC3B) and a-Tubulin expression by WT and JNK∆1, 2 
immortalized MEF after incubation (2 h) without or with 200 nM Rapamycin in the 
presence or absence of 25 µM chloroquine (CQ) was examined by immunoblot 
analysis.  The LC3B-II/Tubulin ratios were normalized to the mean of WT control 
(first lane).  The data presented represent the mean ± SEM; n=3 independent 
experiments; *, p<0.05; **, p<0.01; ***, p<0.001.  Two-way ANOVA was used for 
the analysis of LC3B-II expression and Student’s T test was used for the flux 
analysis. 
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Collectively, these data demonstrate that MAPK8/9 are not required for 
autophagy induced in response to inhibition of TORC1 (by Rapamycin) and 
inhibition of TORC1 plus TORC2 (by Torin1). 
3.2.2 Starvation-induced autophagy does not require MAPK8/9 
Our analysis of the effects of mTOR on autophagy in immortalized MEF 
demonstrated that MAPK8/9 does not regulate autophagy down-stream of mTOR 
(Figure 3.2.).  It was therefore possible that MAPK8/9 functions upstream of 
mTOR in the regulation of autophagy by starvation [28].  To test this hypothesis, 
we examined TORC1 signaling in response to starvation. 
 
 
 
Figure 3.8. RPS6KB1 (p70), pThr-389 RPS6KB1 (P-p70), and GAPDH 
expression by WT and JNK∆1, 2 immortalized MEF after incubation with 
EBSS/5mM glucose (2 or 4h) was examined by immunoblot analysis. 
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We found that starvation prevented the phosphorylation of the TORC1 
substrate Thr-389 RPS6KB1 in both WT and JNK∆1,2 immortalized MEF (Figure 
3.8.).  MAPK8/9 are therefore not required for suppression of TORC1 signaling 
by starvation.  Studies of autophagy demonstrated similar MAP1LC3B puncta 
formation following starvation of WT and JNK∆1,2 immortalized MEF (Figure 3.9.). 
Similarly, no differences in autophagic flux (Figure 3.10.) or accumulation 
of the autophagic substrate SQSTM1 (Figure 3.11.) were detected between WT 
and JNK∆1,2 immortalized MEF.  This analysis suggests that MAPK8/9 in 
immortalized MEF play no required role in starvation-induced autophagy. 
 
 
Figure 3.9. WT and JNK∆1, 2 immortalized MEF were transduced with a lentivirus 
vector that expresses eGFP- MAP1LC3B (eGFP-LC3B).  Puncta formation 
following incubation with EBSS/5 mM glucose (2h) was examined by 
fluorescence microcopy.  Scale bar = 30 µm. 
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Figure 3.10. MAP1LC3B (LC3B) and GAPDH in WT and JNK∆1, 2 immortalized 
MEF after incubation (2 h) in medium or with EBSS/5 mM glucose in the 
presence or absence of 25µM chloroquine (CQ) was examined by immunoblot 
analysis.  The LC3B-II/GapDH ratios were normalized to the average of WT 
control condition (first lane).  The data presented represent the mean ± SEM; n=3 
independent experiments; *, p<0.05; **, p<0.01; ***; p<0.001; ****; p<0.0001.  
Two-way ANOVA was used for the analysis of LC3B-II expression and Student’s 
T test was used for the flux analysis. 
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Figure 3.11. The amount of SQSTM1 (p62) and GAPDH in WT and JNK∆1, 2 
immortalized MEF after incubation with EBSS/5 mM glucose (2 or 4h) was 
examined by immunoblot analysis.  The p62/GAPDH ratio was quantitated and 
normalized to WT cells treated without EBSS (mean ± SEM; n=3 independent 
experiments; *, p<0.05; **, p<0.01; ***; p<0.001 (two-way ANOVA). 
	
3.2.3 MAPK8/9 activation and mTOR inhibition 
Our inability to detect a difference in autophagy between WT and JNK∆1,2 
immortalized MEF was not anticipated.  One explanation for this finding is that 
MAPK8/9 is not regulated under the conditions that we employed for these 
experiments.  Indeed, we found that mTOR inhibition caused by starvation or 
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treatment with Torin1 (Figure 3.12.) under the conditions of the autophagy 
assays did not lead to MAPK8/9 activation. 
 
 
 
Figure 3.12. MAPK8/9 (JNK) activation in immortalized MEF was examined by 
immunoblot analysis of phospho-JNK (P-JNK), JNK, and GAPDH in cells after 
incubation (2 or 4h) with EBSS/5 mM glucose (upper panel) or 250 nM Torin1 
(lower panel).  Lanes 1 & 2 represent positive and negative controls: lysates of 
WT MEF exposed to 60J/m2 UV and JNK∆1, 2 MEF. 
	
It is therefore possible that in a different cell type, or under different culture 
conditions, MAPK8/9 could be activated and thus may contribute to the 
regulation of autophagy during starvation or Torin1 treatment. 
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To test whether MAPK8/9 activation is sufficient for the induction of 
autophagy, we examined the effect of MAPK8/9 activation on the conversion of 
MAP1LC3B-I to MAP1LC3B-II by immunoblot analysis using WT and JNK∆1,2 
immortalized MEF.  We found that activated MAPK8/9 caused no change in 
MAP1LC3B-II formation (Figure 3.13.). 
 
 
Figure 3.13. WT and JNK∆1, 2 immortalized MEF were exposed to UV radiation 
(60J/m2) and cell extracts were prepared at 45 min post-irradiation.  The 
expression of MAP1LC3B (LC3B), phospho-JNK (P-JNK), JNK and GAPDH was 
examined by immunoblot analysis. 
	
These data suggest that MAPK8/9 activation is not sufficient for 
autophagy and that MAPK8/9-promoted autophagy likely involves interactions 
between MAPK8/9 and other pro-autophagic signaling pathways. 
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3.2.4 MAPK8/9 is not required for starvation or Torin1-induced autophagy 
in primary MEF 
Our initial studies of immortalized MEF may be compromised by the loss 
of TRP53 function in these cells, which may change autophagic responses [38].  
We therefore repeated our studies using early passage primary WT and JNK∆1,2 
MEF.  The primary MEF exhibited reduced autophagy flux compared with 
immortalized MEF.  We found that MAPK8/9 deficiency caused no change in 
MAP1LC3B puncta formation in response to starvation (Figure 3.14.). 
 
 
Figure 3.14. 4-Hydroxytamoxifen-treated primary Rosa-CreERT (WT) MEF and 
Rosa-CreERT Mapk8LoxP/LoxP Mapk9-/- (JNK∆1, 2) MEF were examined by 
immunoblot analysis by probing with antibodies to MAPK8/9 (JNK) and a-Tubulin 
(right). WT and JNK∆1, 2 primary MEF were transduced with a lentivirus vector 
that expresses eGFP- MAP1LC3B (eGFP-LC3B).  Puncta formation following 
incubation with EBSS/5 mM glucose (2h and 4h) was examined by fluorescence 
microcopy (right).  Scale bar = 25 µm. 
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Similarly, MAPK8/9-deficiency caused no change in starvation-induced 
autophagic flux (Figure 3.15) or accumulation of the autophagic substrate 
SQSTM1 (Figure 3.16). 
 
 
Figure 3.15. MAP1LC3B (LC3B) and GAPDH expression by WT and JNK∆1, 2 
primary MEF after incubation (2h) in medium or with EBSS/5 mM glucose in the 
presence or absence of 25 µM chloroquine (CQ) was examined by immunoblot 
analysis.  The LC3B-II/GAPDH ratios were normalized to the mean of WT control 
(first lane).  The data presented represent the mean ± SEM; n=3 independent 
experiments; *, p<0.05.  Two-way ANOVA was used for the analysis of LC3B-II 
expression and Student’s T test was used for the flux analysis. 
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Figure 3.16. The amount of SQSTM1 (p62) and a-Tubulin in WT and JNK∆1, 2 
primary MEF after incubation with EBSS/5mM glucose (2h) was examined by 
immunoblot analysis.  The p62/Tubulin ratio was quantitated and normalized to 
p62 expression in WT non-starved cells (mean ± SEM; n=3 independent 
experiments). 
	
Control studies demonstrated that starvation under these conditions did 
not activate MAPK8/9, but did prevent phosphorylation of the TORC1 substrate 
Thr-389 RPS6KB1 (Figure 3.17). 
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Figure 3.17. MAPK8/9 (JNK) activation in WT and JNK∆1, 2 primary MEF was 
examined by immunoblot analysis of phospho-MAPK8/9 (P-JNK), MAPK8/9 
(JNK), and GAPDH after incubation (2h) with media or EBSS/5mM glucose.  WT 
MEF exposed to UV (60J/m2) and JNK∆1, 2 MEF represent positive and negative 
controls (left). RPS6KB1 (p70), pThr-389 RPS6KB1 (P-p70), and a-Tubulin in 
WT and JNK∆1, 2 primary MEF after incubation (2h) with EBSS/5mM glucose was 
examined by immunoblot analysis (upper panel). The amount of p70-S6K1 (p70), 
pThr-389 p70-S6K1 (P-p70), and a-Tubulin in WT and JNK∆1, 2 primary MEF 
after incubation with 250 nM Torin1 (2 or 4 h) was examined by immunoblot 
analysis (lower panel). 
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JNK∆1,2 MEF (Figure 3.17.).  These cells showed similar Torin1-induced 
MAP1LC3B puncta formation (Figure 3.18.). 
 
Figure 3.18. WT and JNK∆1, 2 primary MEF were transduced with a lentivirus 
vector that expresses GFP-LC3.  Puncta formation following incubation with 
250nM Torin1 (2h and 4h) was examined by fluorescence microcopy.  Scale bar 
= 25 µm. 
 
A modest decrease in autophagic flux and modestly increased 
accumulation of the autophagic substrate SQSTM1 was detected in JNK∆1,2 
primary MEF compared with WT primary MEF (Figure 3.19.).  Together, these 
data indicate that MAPK8/9 play no required role in starvation-induced autophagy 
in primary MEF. 
 
3.2.5 Requirement of MAPK8 and MAPK9 for starvation-induced autophagy 
in primary MEF 
It is possible that our analysis of compound MAPK8 plus MAPK9-
deficiency in MEF is compromised by compensatory mechanisms that are 
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engaged in these cells.  Indeed, the role of MAPK8/9 in starvation-induced 
autophagy was first established in studies using Mapk8-/- (JNK∆1) and Mapk9-/- 
(JNK∆2) primary MEF [5].  We therefore examined the effects of starvation on 
WT, JNK∆1, and JNK∆2 primary MEF.  Starvation prevented the phosphorylation 
of the TORC1 substrate Thr-389 RPS6KB1 in these cells (Figure 3.20.). 
 
 
 
Figure.3.19. LC3B and GAPDH expression by WT and JNK∆1, 2 primary MEF after 
incubation (2 h) with 250nM Torin1 without and with 25µM chloroquine (CQ) was 
examined by immunoblot analysis.  Protein band intensity is quantified and 
LC3B-II/GAPDH ratios are graphed (left). Autophagy flux is calculated by 
subtracting LC3B-II/GAPDH ratio in Torin1 condition from Torin1+CQ condition 
(middle). The amount of p62/SQSTM1 and a-Tubulin in WT and JNK∆1, 2 primary 
MEF after incubation with 250 nM Torin1 (2 or 4h) was examined by immunoblot 
analysis.  The p62/Tubulin ratio was quantitated (right). 
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Figure 3.20. The amount of p70-S6K1 (p70), pThr-389 p70-S6K1 (P-p70), and a-
Tubulin in WT, JNK∆1 and JNK∆2 primary MEF after incubation in culture media or 
EBSS/5 mM glucose (2h) was examined by immunoblot analysis. 
	
 
 
Figure 3.21. WT, JNK∆1 and JNK∆2 primary MEF were transduced with a 
lentivirus vector that expresses GFP-LC3B.  Puncta formation following 
incubation of the cells in EBSS/5 mM glucose (left panels) or in media with 250 
nM Torin1 (right panels) was examined by fluorescence microcopy.  Scale bar = 
25 µm. 
	
Studies of WT, JNK∆1, and JNK∆2 primary MEF identified similar 
MAP1LC3B puncta formation (Figure 3.21).  Accumulation of the autophagic 
substrate SQSTM1 (Figure 3.22.), and autophagic flux (Figure 3.23.) were also 
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similar.  These data demonstrate that MAPK8-deficiency and MAPK9-deficiency 
cause no major defects in starvation-induced autophagy. 
 
 
Figure 3.22. The amount of p62/SQSTM1 and a-Tubulin in WT, JNK∆1 and JNK∆2 
primary MEF after incubation in culture media or EBSS/5 mM glucose (2 h) was 
examined by immunoblot analysis. 
	
	
 
Figure 3.23. LC3B and GAPDH expression by WT, JNK∆1 and JNK∆2 primary 
MEF after incubation (2 h) in culture media or EBSS/5 mM glucose without and 
with 25µM chloroquine (CQ) was examined by immunoblot analysis. Protein 
band intensity is quantified and LC3B-II/Gapdh ratios are graphed. 
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3.2.6 Requirement of MAPK8/9 for starvation-induced autophagy in primary 
epithelial cells 
Our analysis of primary and immortalized MEF suggests that MAPK8/9 
plays no required role in starvation-induced autophagy.  However, studies of a 
different cell type may lead to a different conclusion.  We therefore examined 
starvation-induced autophagic flux in primary kidney epithelial cells. 
 
Figure 3.24. LC3B and GAPDH expression by WT and JNK∆1, 2 primary epithelial 
cells after incubation (2h) without or with EBSS/5 mM glucose in the presence or 
presence of 25 µM chloroquine (CQ) was examined by immunoblot analysis.  
Protein band intensity is quantified and LC3B-II/Tubulin ratios are normalized to 
the average of the control (first panel). Autophagy flux is calculated by 
subtracting LC3B-II/Tubulin ratio in EBSS condition from EBSS+CQ condition. 
(middle panel) The amount of p62/SQSTM1 and a-Tubulin in WT and JNK∆1, 2 
primary epithelial cells after incubation with EBSS/5 mM glucose (2h) was 
examined by immunoblot analysis.  The p62/Tubulin ratio was quantitated (right 
panel). (mean ± SEM; n=3 independent experiments) *p<0.05 Two-way ANOVA 
is used for LC3B-II/Tubulin analysis and p62/Tubulin analysis, Student’s T test is 
used for the flux analysis.) 
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We found that MAPK8/9 deficiency caused no difference in autophagic 
flux in these epithelial cells, and no difference in the accumulation of the 
autophagic substrate SQSTM1 (Figure 3.24.) in response to starvation.  These 
data demonstrate that MAPK8/9 has no required role in primary kidney epithelial 
cells for starvation-induced autophagy. 
3.2.7 Requirement of MAPK8/9 for autophagy in response to Ras and 
hypoxia 
If MAPK8/9 are not required for autophagy in response to starvation or 
mTOR inhibition, it is possible that MAPK8/9 may be required for autophagy in 
response to other stimuli. JNK activation is increased in Ras transformed MEFs 
compared to controls (Figure 3.25.) 
 
              
Figure 3.25.	P-JNK, JNK, and GAPDH expression by WT-Puro, WT-HRAS, 
Jnk∆1,2-Puro and Jnk∆1,2-HRas immortalized (p53-/-) MEFs (P12). 
 
We therefore examined Trp53-/- MEF (-Ras) and H-Ras transformed 
(+Ras) Trp53-/- MEF without (WT) and with ablation of the Mapk8 plus Mapk9 
genes (JNK∆1,2) (Figure S8A).  Autophagic flux studies demonstrated no 
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significant effects of MAPK8/9 deficiency (Figure 3.26).  These data indicate that 
MAPK8/9 are not required for autophagy in Control or H-Ras-transformed Trp53-/- 
MEF. 
 
Figure 3.26. LC3B and GAPDH expression by MEFs after 24 h incubation in the 
presence or absence of 25 µM chloroquine (CQ) was examined by immunoblot 
analysis. Protein band intensity is quantified and LC3B-II/Tubulin ratios are 
normalized to the average of WT control condition (First lane). (n=2; Two-way 
ANOVA is used for LC3B-II/Tubulin analysis.) 
	
We also studied Control and H-Ras transformed Trp53-/- MEF without 
(WT) and with ablation of the Mapk8 plus Mapk9 genes (JNK∆1,2) MEF under 
hypoxia (1.5 % O2) conditions (Figure 3.27.).  Autophagic flux studies 
demonstrated no significant effects of MAPK8/9 deficiency (Figure 3.28.).  These 
data indicate that MAPK8/9 are not required for autophagy in Control or H-Ras-
transformed Trp53-/- MEF under hypoxia conditions. 
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Figure 3.27. P-JNK, JNK, and GAPDH expression by WT-Puro, WT-HRAS, 
Jnk∆1,2-Puro and Jnk∆1,2-HRas immortalized (p53-/-) MEFs (P12) after 24 h 
incubation in 1.5% O2. 
 
                            
Figure 3.28. LC3B and GAPDH expression by MEFs after 24 h incubation in 
1.5% O2 in the presence or absence of 25 µM chloroquine (CQ) was examined 
by immunoblot analysis. Protein band intensity is quantified and LC3B-II/Tubulin 
ratios are normalized to the average of WT control condition (First lane). 
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3.2.8 MAPK8/9-regulated autophagy in primary hepatocytes 
Autophagy plays a major role in systemic metabolic homeostasis [39] and 
hepatic lipid metabolism [40].  Moreover, hepatocytes have been reported to 
exhibit MAPK8/9-dependent autophagy [6].  We therefore examined the 
requirement of MAPK8/9 for autophagy using primary hepatocytes prepared from 
Alb-cre-/+ (Control) mice and Alb-cre-/+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP (JNK∆1,2) 
mice.  We found that JNK∆1,2 hepatocytes exhibited increased accumulation of 
MAP1LC3B-II following lysosomal inhibition and the reduced accumulation of the 
autophagic substrate SQSTM1 in JNK∆1,2 hepatocytes compared with Control 
hepatocytes (Figure 3.29.).  These observations suggest that MAPK8/9 may 
inhibit autophagy in hepatocytes. 
 
 
Figure 3.29. MAP1LC3B (LC3B) and a-Tubulin in WT and JNK∆1, 2 primary 
hepatocytes after incubation (6 h) with medium or EBSS/5 mM glucose in the 
presence or absence of 25µM chloroquine (CQ) was examined by immunoblot 
analysis (upper panel). The amount of SQSTM1 (p62) and a-Tubulin in WT and 
JNK∆1, 2 primary hepatocytes was examined by immunoblot analysis. 
+-WT JNK
∆1,2
+-
LC3B-I
LC3B-II
Tubulin
CQ +-WT JNK
∆1,2
+-
p62
Tubulin
  139 
To confirm the conclusion that MAPK8/9 suppresses autophagic flux in 
primary hepatocytes, we examined wild-type (WT) hepatocytes treated with JNK-
in-8, a potent and selective small molecule inhibitor of MAPK8/9 [41].  We found 
that treatment with JNK-in-8 caused increased accumulation of MAP1LC3B-II 
following lysosomal inhibition and reduced accumulation of the autophagic 
substrate SQSTM1 (Figure 3.30.).  These data indicate that pharmacological 
inhibition of MAPK8/9 causes increased autophagic flux. 
 
 
 
Figure 3.30. WT primary hepatocytes were incubated (6 h) without or with 2 µM 
JNK-in-8.  MAP1LC3B (LC3B) and a-Tubulin in WT and JNK∆1, 2 primary 
hepatocytes in the presence or absence of 25 µM CQ was examined by 
immunoblot analysis (C).  The amount of SQSTM1 (p62) and a-Tubulin was 
examined by immunoblot analysis (D). 
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The increased autophagy caused by MAPK8/9 loss-of-function in 
hepatocytes compared with WT hepatocytes was unexpected.  This increased 
autophagy may reflect the established role of MAPK8/9 to strongly suppress the 
transcriptional activity of the PPARa nuclear receptor [42] that can promote 
autophagy through increased expression of autophagic genes [43].  This role of 
MAPK8/9 to suppress basal autophagy in hepatocytes is similar to the 
established function of MAPK8/9/10 in neurons to suppress basal autophagy by 
repression of autophagic gene expression [27]. 
 
3.3 DISCUSSION 
Studies of the genetically tractable organism Drosophila demonstrate that the 
basket gene (encodes a MAPK8/9 ortholog) can increase autophagy [44].  It is 
established that Basket in Drosophila promotes autophagy by causing increased 
expression of autophagy proteins [44].  This mechanism is also found in 
mammals [45-51].  Thus, MAPK8/9 may promote autophagy by increasing the 
expression of ATG4 [49], ATG5 [45], BECN1 [48], BNIP3 [47, 50], MAP1LC3B 
[46, 51], and SQSTM1 [46].  MAPK8/9-regulated gene expression therefore 
represents an evolutionarily conserved mechanism of autophagic regulation.  
The specific physiological effects of MAPK8/9 on the expression of autophagic 
proteins likely reflects the combinatorial actions of MAPK8/9-regulated 
transcription factors together with other transcription factors that are activated by 
different signal transduction pathways.  MAPK8/9 may therefore play an essential 
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role in mammalian autophagy in some specific physiological or pathological 
contexts. 
Recently, MAPK8 was proposed to promote starvation-induced autophagy 
in MEF by a non-transcriptional mechanism [5].  Mapk8-/- (JNK∆1) MEF, but not 
Mapk9-/- (JNK∆2) MEF, were reported to be resistant to starvation-induced 
autophagy [5].  The mechanism was proposed to be mediated by 
phosphorylation of BCL2 (on Thr-69, Ser-70, and Ser-87) by MAPK8, disruption 
of BCL2/BECN 1 complexes, and the initiation of BECN1-dependent autophagy 
[5].  This mechanism implies that MAPK8 is essential for BCL2 phosphorylation 
[5].  However, other studies indicate that MAPK8 may only serve a redundant 
role in BCL2 phosphorylation [20, 30-34].  The essential non-transcriptional role 
of MAPK8 in starvation-induced autophagy [5] is therefore likely to be mediated 
by BCL2 phosphorylation only in specific cellular contexts. 
Possible roles of MAPK8 in starvation-induced autophagy include functional 
interactions with TORC1, a master regulator of starvation-induced autophagy [4].  
Indeed, previous studies have demonstrated that MAPK8/9 can be activated in 
response to TORC1 signaling [35] and that TORC1 activation can require 
MAPK8/9 signaling [28].  However, we found no requirement for MAPK8/9 
upstream (Figure 1) or downstream (Figure 2) of TORC1 during starvation-
induced autophagy.  The essential function of MAPK8/9 must therefore play a 
role in a pathway that is parallel to TORC1.  These observations led us to test 
whether MAPK8/9 is required for starvation-induced autophagy.  Our analysis 
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demonstrates that MAPK8/9 is not required for starvation-induced autophagy in 
mouse fibroblasts or epithelial cells (Figures 2 & S7). 
Many reported studies support the conclusion that MAPK8/9 plays an essential 
role in the promotion of autophagy [5-23]. In contrast, our analysis does not 
indicate a major role for MAPK8/9 in starvation-induced autophagy.  It is likely 
that small differences in cell culture conditions and starvation conditions may 
contribute to discrepancies between our analysis (Figure 2) and previously 
published reports of the role of MAPK8/9 in MEF [5].  The use of the small 
molecule SP600125, that inhibits MAPK8/9 and many other protein kinases [52], 
to draw conclusions concerning the specific role of MAPK8/9 may also contribute 
to conclusions [8, 10, 12-19, 22, 51] that contrast with those drawn from our 
analysis of MAPK8/9 knockout cells.  Finally, some studies that have identified a 
role for MAPK8/9 do not focus on starvation-induced autophagy.  One example is 
the requirement of MAPK8/9 for oncolytic adenovirus-mediated autophagy [20].   
Clearly our conclusions concerning the lack of a major role for MAPK8/9 in 
autophagy are restricted to the starvation, transformation, and hypoxia 
paradigms that we studied and it is likely that MAPK8/9 may play a key role in 
autophagy caused by other agents. 
In conclusion, our analysis demonstrates that there is no required role for 
MAPK8/9 in starvation-induced autophagy.  However, this signaling pathway can 
regulate autophagy by a conserved mechanism that leads to regulated 
expression of autophagy proteins in Drosophila [44] and mammals [45-51].  
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MAPK8/9-regulated gene expression may lead to increased autophagy, but 
different paradigms of MAPK8/9-regulated gene expression could lead to 
reduced autophagy.  For example, MAPK8/9-regulated gene expression 
suppresses basal autophagy in neurons [27].   A similar mechanism may account 
for MAPK8/9-mediated repression of autophagy in hepatocytes (Figure 5).  It is 
also possible that MAPK8/9 may promote autophagy by a non-transcriptional 
mechanism mediated by BCL2 phosphorylation in some specific physiological or 
pathological conditions.  Collectively, our analysis shows that the role of 
MAPK8/9 in autophagy may be context-dependent and substantially more 
complex than previously considered. 
 
3.4 METHODS 
3.4.1 Cell culture 
3.4.1.1 Primary MEFs 
Primary MEF were prepared from embryonic day 13.5 WT, Mapk8-/-, 
Mapk9-/-, Rosa-CreERT and Rosa-CreERT Mapk8LoxP/LoxP Mapk9-/- mice and 
cultured in DMEM supplemented with 10% FBS, 1% penicillin /streptomycin plus 
1% L-glutamine (Invitrogen) [53].  CreERT primary MEF were treated (24 h) with 1 
µM 4-hydroxytamoxifen (Cat. No. H7904; Sigma) in culture media at passage #1.  
Autophagy experiments were conducted on MEF between passages #2 and #3. 
 
 
  144 
3.4.1.2 Immortalized MEFs 
Immortalized WT and Mapk8-/- Mapk9-/- (JNK∆1,2) MEF have been 
described previously [54].  We have also described Trp53-/- MEF, Trp53-/- Mapk8-
/- Mapk9-/- MEF, H-Ras transformed Trp53-/- MEF, and H-Ras transformed Trp53-
/- Mapk8-/- Mapk9-/- MEF [55].  These cells were cultured in DMEM supplemented 
with 10% FBS, 1% penicillin /streptomycin plus 1% L-glutamine (Invitrogen). 
3.4.1.3 Kidney Epithelial Cells 
Primary kidney epithelial cells were isolated from Rosa-CreERT mice or 
Rosa-CreERT Mapk8LoxP/LoxP Mapk9-/- mice.  Kidneys were digested (2 h) with 
0.1% collagenase plus 0.1% trypsin in DMEM with 150 mM NaCl [56]. The cells 
were maintained in DMEM/F12 media containing 10% fetal bovine serum plus 
150mM urea and 150mM sodium chloride.  The cells were treated (24 h) with 1 
µM 4-hydroxytamoxifen and employed for autophagy studies after 3 days. 
3.4.1.4 Primary Hepatocytes 
Primary hepatocytes were isolated from WT (Alb-Cre+) and MAPK8/9-
deficient (Alb-Cre+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP) mice [42] using a modified 2-
step perfusion method [57] with Liver Perfusion Media and Liver Digest Buffer 
(Invitrogen). Cells were seeded on plates (pre-coated (1 h) with collagen I (BD 
Biosciences) in DMEM supplemented with 10% FBS, 2 mM sodium pyruvate, 1 
μM dexamethasone, 100 nM insulin plus 2% penicillin/streptomycin.  After 
attachment (2 h), the medium was removed and the hepatocytes were incubated 
(22 h) in maintenance medium (DMEM (4.5g/L glucose)) supplemented with 10% 
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FBS, 0.2% BSA, 2 mM sodium pyruvate, 2% Pen/Strep, 0.1 μM dexamethasone, 
1 nM insulin).  Autophagy studies were performed within 48 h.  Pharmacological 
studies of MAPK8/9 inhibition were performed by treating hepatocytes with 2 µM 
JNK-in-8 (Millipore Sigma Cat. No. 420150) or solvent (DMSO). 
3.4.1.5 Autophagy studies 
Autophagy promoted by amino acid starvation was examined using cells 
(70% confluent) washed three times with Earle’s Balanced Salt Solution (EBSS) 
and then incubated with EBSS/5mM glucose.  Autophagy was also examined in 
cells treated with a pharmacological inhibitor of mTOR (250nM Torin1; Tocris, 
cat. No. 4247) and TORC1 (200nM Rapamycin; Millipore Sigma, cat. No. R8781) 
or under hypoxia (1.5 % O2) conditions.  Autophagic flux was examined by 
measuring the MAP1LC3B-II / GAPDH ratio (or MAP1LC3B-II / a-Tubulin ratio) 
by immunoblot analysis, normalization of the data to the control condition 
(without autophagy induction or CQ), and calculation of the increased 
MAP1LC3B-II / GAPDH ratio caused by treatment of the cells with 25 µM 
chloroquine diphosphate (CQ) (Fluka Biochemika, Cat. No.25745) to inhibit 
lysosomal protein degradation [36]. 
3.4.1.6 Immunoblot analysis 
Cell extracts were prepared using Triton lysis buffer (20 mM Tris at pH 
7.4, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, 10 µg/mL aprotinin plus leupeptin).  Extracts (20–40 μg of protein) were 
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examined by protein immunoblot analysis by probing with antibodies described in 
antibodies section.  Immunocomplexes were detected using IRDye conjugated 
secondary antibodies (LI-COR) and quantitated by using the Odyssey infrared 
imaging system (LI-COR Biosciences). 
3.4.1.7 Antibodies 
ATK (Cat No. 9272), pThr308 AKT (Cat No. 5106), pSer-473 AKT (Cat 
No. 9271), pThr-183, pTyr-185 MAPK8/9 (Cat. No. 9255), MAP1LC3B (Cat. No. 
2775), RPS6KB1 (Cat. No. 9202), pThr-389 RPS6KB1 (Cat. No. 9206) 
antibodies were from Cell Signaling.  The SQSTM1 antibody (Cat. No. GP62-C) 
was from Progen, the MAPK8/9 antibody (Cat. No. AF1387) was from R&D 
Systems, the aTubulin antibody (Cat. No. T5168) was from Millipore Sigma, and 
the GAPDH antibody (Cat. No. sc-25778) was from Santa Cruz. 
3.4.1.8 MAP1LC3B puncta formation 
Cells were transduced with a lentiviral vector that expresses eGFP-
MAP1LC3B according to the manufacturer’s instructions (LentiBrite eGFP-LC3 
Lentiviral Biosensor; EMD Millipore, Cat. No. 17-10193).  The cells were plated 
on a glass culture dish and incubated with culture media, EBSS/5mM glucose, or 
culture media supplemented with 250 nM Torin1.  Live cell images were acquired 
at 0, 2, and 4 hours using Leica TCS SP2 confocal microscope and Leica 
Confocal Software. 
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3.4.1.9 Statistical Analysis 
Data are presented as the mean and standard error.  Statistical analysis 
was performed using two-tailed Student’s t-test for pair-wise comparisons and, 
two-way ANOVA for multiple group comparisons as indicated at the figure 
legends 
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4.1 Summary of the results 
The data presented in Chapter-2, section 2 demonstrate that pancreatic b-
cell specific Mapk8ip1 (Jip1) gene ablation results in decreased insulin secretion 
in response to glucose.  This conclusion is supported by both in-vivo (mice) and 
ex-vivo (isolated pancreatic islets) insulin release assays.  JIP1 deficient mice do 
not show a decrease in the expression of Insulin1 and Insulin2 genes 
(determined by quantitative mRNA analysis of isolated islets).  In addition, insulin 
content of the islets (determined by ELISA), and the average islet size 
(determined by insulin staining of pancreas sections) are similar in JIP1 deficient 
and control mice.  These findings suggest that JIP1 may have a function in the 
regulation of insulin secretion, rather than its production.   
JIP1 is implicated in the regulation of vesicle trafficking in neurons[1, 2] 
through interacting with kinesin[3, 4] and dynactin[5, 6] complexes.  In this study, 
I showed that the islets isolated from JIP1Y705A mutant mice that lack the JIP1-
kinesin interaction, can recapitulate the insulin secretion defect observed in JIP1 
deficient islets.  This finding supports the concept that the JIP1-kinesin 
interaction may play a role in insulin vesicle trafficking in b-cells. 
Fu et al. suggested that JNK activation can enhance kinesin-mediated 
anterograde trafficking of JIP1 in neurons[6].  I tested a possible role of JIP1-JNK 
interaction in glucose-stimulated insulin secretion from b-cells by studying the 
islets from JIP1∆JBD mutant mice that has disrupted JIP1-JNK interaction.  Both 
JIP1∆JBD mutant islets, and wild type islets treated with a JNK-inhibitor showed a 
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decreased insulin secretion in response to glucose.  These findings support the 
concept that JNK positively regulates JIP1 mediated insulin secretion.  On the 
other hand, Morfini et al. suggested that the phosphorylation of kinesin by JNK 
results in the dissociation of kinesin and its cargo from the microtubules[7, 8].  
Thus, it is possible that JNK may have a dual role in insulin secretion.  First, JNK 
may mediate insulin vesicle trafficking via phosphorylating JIP1.  Second, JNK 
may induce insulin release at the secretion site via phosphorylating kinesin.  
These and other possible mechanisms that may contribute to the JIP1 mediated 
insulin secretion are discussed in more detail in the following sections. 
JIP1 is implicated in the trafficking of autophagosomes in neurons[1]. 
Moreover, studies suggest a role for autophagy in both b-cell survival and insulin 
secretion[9-12].  Thus, in addition to the possible roles of JIP1 and JNK in insulin 
vesicle trafficking, JIP1-JNK signaling may also contribute to the autophagy 
regulation.  On the other hand, it is not clear if JNK plays a role in the promotion 
or suppression of autophagy[13, 14].    
The results discussed in Chapter-3 show that JNK is not essential for 
starvation-induced autophagy induction in mouse embryonic fibroblasts (MEF).  
Our results indicate a need for re-evaluation of the previously published reports 
which show a requirement of the JNK signaling for starvation-induced autophagy.  
Furthermore, we showed that JNK deficiency increases basal autophagy levels in 
primary hepatocytes, suggesting that the role of JNK in autophagy can be 
variable depending on the cellular context.  On the other hand, these findings do 
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not eliminate a possible role for JIP1-JNK signaling in the regulation of 
autophagy in beta-cells, and a possible contribution of this role to insulin 
secretion. 
Potential mechanisms related to our main findings and, approaches that 
can evaluate these mechanisms are discussed in more detail in the following 
section. 
 
4.2 Discussion and outlook 
 
4.2.1 JIP1-JNK signaling in insulin vesicle trafficking and secretion 
Insulin is a polypeptide hormone, synthesized as pre-proinsulin in the 
rough ER. By the cleavage of its N-terminal hydrophobic signal sequence, it is 
converted into pro-insulin, which consists of A-chain (21 amino acids), B-chain 
(29 amino acids), and C-peptide[15].  Pro-insulin is packed into immature insulin 
vesicles in the trans-golgi system where the A-chain and the B-chain are linked 
by disulfide bonds. During maturation, acidification of vesicles mediates cleavage 
of the pro-insulin to insulin and C-peptide[16, 17]. Insulin is crystalized in the 
presence of zinc and calcium as the vesicle matures[18], which results in the 
typical morphology of the insulin vesicles detected by electron microscopy, a 
dense core (crystalized insulin) surrounded by a halo[19-21].  Upon stimulation, 
both insulin and the C-peptide is released into the circulation via the portal vein. 
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Insulin secretion requires trafficking of newly synthesized mature insulin 
vesicles to the secretion site (where endocrine cells are in contact with the 
endothelial cells of the capillary system) and, release of the insulin granules from 
the plasma membrane[22].  Upon stimulation, an increase in the intracellular 
Ca++ levels trigger the insulin release from beta-cells[22].  Many proteins are 
proposed to mediate pre-docking of the vesicles to the plasma membrane and 
Ca++ stimulated vesicle release, such as SNAREs (VAMP1[23], and 
Syntaxin4[24]), calcium-regulated proteins (Synaptotagmin I, II[25], III[26], 
VII[26],V, VII[27], VIII, IX[28, 29]), Munc18[24, 30], and granuphilin[31]  
The studies presented in chapter-2, showing a role for the JIP1-kinesin 
interaction in insulin secretion indicate that JIP1 may contribute to insulin vesicle 
trafficking.  However, it is unknown whether JIP1 can directly interact with insulin 
vesicle-associated proteins.  JIP1 can interact with other vesicle membrane-
associated proteins, such as LC3B[1] (Autophagosomes), Rab10[32], 
ApoER2[33], and LRP2[34].  Previous studies proposed a role for JIP1 in vesicle 
trafficking via the interaction of JIP1 with these vesicle-associated proteins[1, 2, 
32].  In chapter 2, my findings suggested a parallel role for JIP1 in pancreas b-
cells, where it may mediate insulin vesicle trafficking via interactions with kinesin. 
It is unlikely that JIP1 can directly bind to the insulin vesicle membrane, since, 
unlike JIP3[35] and JIP4[36], JIP1 doesn’t have a predicted transmembrane 
domain[37].  However, JIP1 and JIP3 can form heterodimers[38, 39], thus, 
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evaluation of JIP3 and insulin vesicle interaction may be of importance for a 
possible JIP1-insulin vesicle interaction through JIP3.   
A useful approach to understand whether JIP1 plays a role in insulin 
vesicle trafficking would be to evaluate the existence of direct or indirect 
interactions between JIP1 and insulin vesicle-associated proteins.  BioID (The 
proximity-dependent biotin identification method) is a proteomics based method 
that enables the identification of the interaction partners of a protein by proximity-
dependent biotinylation[40].  In this method, the protein of interest is fused with a 
biotin protein ligase at its C-terminus or N-terminus.  In-vivo biotinylated proteins 
are then isolated via streptavidin pull-down and analyzed by mass spectrometry.  
Applying this method to JIP1 in the context of beta-cells can be useful to identify 
the candidate interaction partners of JIP1 in beta-cells. 
In addition to the role of the JIP1-kinesin interaction in insulin secretion, 
my findings suggest that the JIP1-JNK interaction also contributes to the 
regulation of glucose-induced insulin secretion.  The possible mechanisms for 
the role of JNK-JIP1-kinesin crosstalk in glucose-induced insulin secretion are 
discussed below. 
Hypothesis-1: JIP1 phosphorylation by JNK enhances the kinesin-mediated 
insulin vesicle trafficking (Figure 4.1.) 
 
 Fu et al. proposed that, the interaction of phosphorylated JIP1 (on Ser421) 
with the kinesin heavy chain can be sufficient to activate the kinesin transport on 
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the microtubules[6].  This study supports the concept that JIP1 phosphorylation 
by JNK can regulate JIP1-mediated cargo trafficking.  My findings showed that 
both inhibition of the JIP1-JNK interaction by genetic mutation and the inhibition 
of JNK activity by a pharmacological inhibitor in isolated islets, resulted in 
decreased glucose-stimulated insulin secretion.  Thus, upon glucose stimulation, 
JNK may be activated to stimulate kinesin mediated JIP1-insulin vesicle complex 
trafficking, which may be related to the reported role of kinesin in insulin 
secretion[41, 42]. 
 
 
Figure 4.1: Cartoon presenting the hypothetical model, where JIP1 interacts with 
kinesin for tethering insulin vesicles to the microtubules; and upon glucose 
stimulation, activated JNK phosphorylates JIP1 to initiate anterograde trafficking. 
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 Tanabe et al. reported that JNK activation is not induced in islets cultured 
in high glucose for long durations[43].  However, my results show that JIP1 
deficient islets display moderately decreased JNK activation compared with 
control islets after a high glucose stimulation.  Glucose-stimulated insulin 
secretion is a very prompt response, taking place within minutes after glucose 
stimulation.  Future studies to measure time course of JNK activation in isolated 
primary islets would identify the dynamic regulation of JNK activation during early 
and late response of b-cell to glucose.   
 The data presented in Chapter-2 shows that treatment of isolated wild 
type islets with a pharmacological JNK-inhibitor (JNK-in-8) can suppress 
glucose-induced insulin secretion.  In addition, disruption of JIP1-JNK interaction 
with a genetic mutation recapitulated this phenotype.  These findings support the 
concept that JIP1-JNK crosstalk is important for the glucose-stimulated insulin 
secretion.   
Further studies can be performed to confirm this conclusion.  For instance, 
insulin release assays using isolated islets from mice with null mutations at JIP1 
phosphorylation sites could be tested to assess if JIP1 phosphorylation is 
required for insulin secretion.  Additionally, using mouse models with beta-cell 
specific JNK deletion to test islet function would confirm the role of JNK in 
glucose-stimulated insulin release. 
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Hypothesis-2: Kinesin phosphorylation by JNK dissociates kinesin from 
microtubules, and releases insulin vesicle at the secretion site (Figure 4.2.) 
 
Overexpression of JIP1 in Drosophila causes an accumulation of 
immobilized vesicles in the axons of neurons[2].  The presence of a scaffold 
protein in excess amounts compared to the other signaling components can 
inhibit signaling complex assembly by sequestration of signaling components on 
different scaffolds[37, 44].  Therefore, the inhibition of vesicle transport in JIP1-
overexpressing Drosophila may be a consequence of an inhibition JNK signaling.  
Concordantly, co-overexpression of JNK, together with JIP1 resulted in an 
increased JNK activation, and decreased immobile vesicle accumulation in the 
axons.  This finding was accompanied by a decreased JIP1-Kinesin association, 
suggesting that increased JNK signaling may result in the dissociation of JIP1 
and its cargo from kinesin[2].  Similarly, Morfini et al. proposed that JNK-
mediated kinesin phosphorylation results in dissociation of kinesin from 
microtubules, and inhibits kinesin-mediated cargo transport[7, 8].   
Taken together, it is possible that, JIP1-JNK interaction in b-cells may 
contribute to insulin vesicle release from microtubules at the secretion site 
(Figure 4.2.).  Evaluating vesicle recruitment to the membrane and glucose-
stimulated vesicle release in JIP1 deficient and control b-cells can help to test 
this hypothesis.  Decreased vesicle release in the presence of similar vesicle 
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recruitment to the membrane would support a possible role for JIP1-JNK 
signaling in insulin vesicle dissociation. 
 
 
Figure 4.2: Cartoon presenting the hypothetical model, where JNK 
phosphorylates kinesin at the secretion site, which results in dissociation of 
kinesin and its cargo from microtubules, and consequently release of insulin. 
 
To evaluate the recruitment of the insulin vesicles to the plasma 
membrane, total internal reflection fluorescence (TIRF) microscopy in live cells 
can be used[45]. Previously, a mouse model that expresses insulin-mCherry 
fusion protein in beta-cells was reported[46].  Crossing the insulin-mCherry mice 
with JIP1∆ISL mice to generate Mapk8ip1LoxP/LoxP, MIP-Cre+/-, Insulin-mCherry+ 
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mice would be useful to measure the in-vivo insulin-vesicles that are proximal to 
the plasma membrane in JIP1 deficient beta-cells.  
Although TIRF microscopy is a powerful method to image vesicle 
dynamics at the plasma membrane, it does not give information regarding the 
vesicle release.  The FluoZin-3 dye, which is cell-impermeable and becomes 
fluorescent upon Zn+2 binding, can be used to detect the release of Zn+2 rich 
insulin vesicles from beta-cells[47].  Another method that can be used to test if 
vesicle release is impaired in JIP1 deficient islets is carbon fiber amperometry 
method, which can quantitatively monitor the exocytosis of vesicles[48].  
 
4.2.2 JIP1-RalA interaction in JNK activation and insulin secretion 
JIP1 can interact with RalA, a member of the Ras small GTPase 
superfamily, and this interaction is proposed to be important for RalA-induced 
JIP1-mediated JNK activation in response to reactive oxygen species (ROS) in 
non-endocrine cells[49].   
RalA is a regulator of endosomal membrane trafficking pathways[50], and 
previous studies reported that RalA can regulate hormone secretion from 
neuroendocrine cells[51, 52].  In addition, Lopez et al. showed that shRNA 
knockdown of RalA in islets isolated from wild type mice resulted in decreased 
glucose stimulated insulin secretion from perifused islets.  Decreased cell 
membrane capacitance change in RalA deficient insulinoma cells suggests that 
that RalA may play a role in the insulin vesicle exocytosis[53].  Moreover, RalA 
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can interact with voltage-gated Ca++ channels and tether insulin vesicles to 
regulate bi-phasic insulin release[54].  Depletion of Sec5, a downstream effector 
of RalA, in b-cells results in decreased insulin release induced by membrane 
depolarization[55].  This phenotype is similar to my observation that JIP1 
deficient islets display decreased insulin secretion after membrane depolarization 
induced by KCl treatment. 
 
Hypothesis-3: Glucose-induced activation of RalA can induce JIP1-mediated JNK 
activation in b-cells to mediate insulin secretion in response to glucose 
 
It is possible that activated RalA signaling play a role upstream of JIP1-
JNK pathway in glucose-stimulated b-cells.  RalA activation occurs as early as 5 
minutes after secretagogue stimulation of insulinoma cells[56].  If JNK acts 
downstream of RalA signaling in glucose-stimulated insulin secretion, knockdown 
of RalA in wildtype islets would result in decreased JNK activity in high glucose 
condition, similar to the finding we observed in JIP1 deficient islets.  In addition, if 
decreased JIP1-mediated JNK activity that I have observed is dependent on the 
JIP1-RalA interaction, depletion of RalA in JIP1 deficient islets should not result 
in further decrease in activated JNK levels. 
Evaluating whether JIP1 and RalA co-immunoprecipitate from protein 
lysates of isolated islets incubated with low or high glucose can test not only the 
possible JIP1-RalA interaction in b-cells, but also if this interaction is regulated by 
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glucose stimulus.  Furthermore, fluorescence imaging using low or high glucose 
treated islets, can test whether a possible JIP1-RalA interaction is localized to the 
plasma membrane or another relevant cellular compartment.  Together, these 
experiments can provide insight in the possible role of RalA upstream of JIP1-
JNK signaling in b-cells. 
 
4.2.3 JIP1-JNK signaling in microtubule organization and insulin secretion 
The role of JIP1 and JNK signaling in vesicle trafficking has been studied 
mostly in neuronal cells[1, 2, 6-8, 57]. In neurons, microtubules are radially 
oriented from the perinuclear region to the cell periphery and axons; and vesicles 
are transported bi-directionally on the axonal microtubules for long distances[58]. 
On the other hand, insulin secreting beta-cells have a mesh-like, non-directional 
microtubule distribution throughout the cytoplasm[42, 59].  Zhu et al. reported 
that the dense, mesh-like distribution of microtubules in beta-cells can limit the 
availability of insulin vesicles to the secretion site by mediating their withdrawal 
from the membrane, and by trapping them in the cell interior[46].  In endocrine 
cells, the Golgi is the main site of microtubule origination[60].  Zhu et al. showed 
that glucose stimulation caused de-polymerization of existing microtubules in 
beta-cells, and an increase in new microtubule polymerization originating from 
the Golgi[46].  Moreover, de-polymerization of microtubules by nocodazole 
treatment increased the glucose-stimulated insulin secretion, whereas increasing 
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the microtubule stability by taxol treatment inhibited glucose responsiveness of 
the b-cells[46].   
Microtubule plasticity is modulated by microtubule associated proteins 
(MAPs)[61].  JNK can phosphorylate MAPs to regulate microtubule stability, and 
bundling in neurons[62].  For instance, JNK can phosphorylate SCG10/STMN2 
(MAP)[63], MAP2, and MAP1B[64] which contributes to the regulation of 
microtubule assembly, stability and axonal length.  It is reported that in b-cells 
phosphorylation of microtubule associated protein MAP2 can mediate Ca-
triggered insulin secretion[65].   
JIP1 can also interact with Tau (MAP-II) and is implicated in its 
phosphorylation and subcellular localization.  Moreover, overexpression of MLK3, 
which can bind JIP1 and activate JNK[44], resulted in increased microtubule 
stability, while siRNA depletion of MLK3 increased the sensitivity of cells to taxol, 
a microtubule stabilizing agent[66].  Taken together, it is possible that decreased 
glucose-stimulated insulin secretion in JIP1 deficient b-cells is a result of altered 
microtubule plasticity.   
 
Hypothesis-4: JIP1-mediated JNK activation and microtubule-associated protein 
phosphorylation by JNK may modulate microtubule plasticity and glucose 
responsiveness in b-cells (Figure 4.3.) 
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Figure 4.3. Cartoon presenting the hypothetical model, where JNK 
phosphorylates microtubule associated proteins in response to glucose, which 
results in the alteration of the dense microtubule network and enhanced 
mobilization of the insulin vesicles to the secretion site. 
 
Imaging microtubule density in control and JIP1 deficient islets under low 
glucose and high glucose conditions would be useful to evaluate whether 
microtubule plasticity is altered in JIP1 deficient b-cells in response to glucose 
stimulation.  First, JIP1 deficient b-cells may display an increased microtubule 
density compared with controls.  This result would support the idea that 
increased microtubule density in JIP1 deficient b-cells can withhold the insulin 
vesicles away from secretion site and decrease glucose-stimulated insulin 
release.  In this case, treatment of JIP1 deficient islets with nocodazole 
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(microtubule destabilizing agent) during a high glucose perifusion of the islets 
would rescue the glucose-stimulated insulin secretion defect observed in the 
mutant islets.  Second, microtubule density in JIP1 mutant islets may be similar 
or decreased when compared with the controls, but there may be a decrease in 
the microtubule plasticity in response to glucose[46].  This finding would support 
the hypothesis that JIP1-mediated JNK signaling may regulate the microtubule 
associated protein phosphorylation and microtubule plasticity in response to 
glucose. 
In addition to the study in b-cells discussed above, Bargi-Souza et al. 
showed a similar finding regarding the microtubule dynamics during thyroid 
stimulating hormone (TSH) secretion from the pituitary gland[67].  In this study, 
rats with thyroidectomy (removal of thyroid gland) showed increased TSH 
secretion caused by the absence of thyroid hormones, and consequently the 
absence of negative feedback inhibition. Increased TSH secretion was 
accompanied by a decrease in tubulin and actin staining in the pituitary gland.  
Moreover, recovery of negative feedback inhibition by hormone replacement 
therapy in these rats increased tubulin and actin density in the pituitary gland[67].  
Altogether, these studies suggest that a possible inhibitory effect of dense 
microtubule network on hormone secretion can be a regulatory mechanism in 
both b-cells and pituitary gland.   
To test if TSH granules in pituitary gland are surrounded by a dense 
microtubule network as seen in b-cells, I have stained WT pituitary gland 
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sections with antibodies to b-TSH and a-tubulin.  Confocal images of stained 
pituitary gland sections in Figure 4.4. suggest that TSH granules in pituitary gland 
are surrounded by a dense tubulin network, similar to the insulin vesicles in 
pancreas b-cells[46].   
TSH secretion from the anterior pituitary gland is stimulated by Thyrotropin 
Releasing Hormone (TRH).  Microtubule imaging by super resolution microscopy 
in JIP1 deficient and control pituitary glands before and after TRH induction can 
be useful to evaluate the microtubule plasticity in response to TRH induction.  In 
addition, nocodazole and TRH combined treatment of JIP1 deficient and control 
pituitary glands would show whether microtubule depolarization can rescue TRH-
induced TSH secretion defect in JIP1 deficient pituitary glands. 
 
 
Figure 4.4. Pituitary glands were dissected and fixed in formalin overnight.  After 
processing with ethanol gradients, tissues were embedded in paraffin.  7µm thick 
sections were cut and rehydrated before staining with antibodies to a-tubulin and 
b-TSH.  Images were obtained using Leica confocal microscope. 
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4.2.4 JIP1, primary cilium, and insulin secretion 
Most of the terminally differentiated cells, including b-cells, have a primary 
cilium[68, 69].  The primary cilium is an antenna-like cell protrusion that is formed 
by centrioles near the plasma membrane and can function as the sensor of the 
cells[70-72].  The primary cilium is linked to the planar cell polarity pathway, and 
functions in regulating the cellular signaling such as Wnt[73], Notch[74], and 
Hedgehog[75]. 
The primary cilium is implicated in b-cell function and regulation of insulin 
secretion[76].  For instance, islets from mouse with Bardet-Biedl-Syndrome 4 
(Bbs4) mutation exhibited decreased glucose-stimulated insulin secretion[77].  
Bbs4 mutation impairs cilia function, while the cilia are structurally intact[78].  
This result suggests that, cellular signaling mediated by primary cilium may be 
important for the regulation of insulin secretion.   
By immunofluorescence imaging of pancreas sections, I have detected 
puncta staining of JIP1 in the islets (Figure 4.5.), which indicates a possible 
specific and functional sub-cellular compartmentalization of JIP1 in b-cells. 
Additionally, in dispersed islets, JIP1 staining was observed throughout 
the cytoplasm and nucleus, with a denser spot near the plasma membrane.  This 
dense local staining co-localized with g-tubulin staining a marker used for basal 
body detection (Figure 4.6.).  Also, immunofluorescence staining of intact 
isolated islets recapitulated the JIP1 co-localized with g-tubulin (Figure 4.7.). 
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Figure 4.5. Paraffin embedded pancreas sections from JIP1 deficient (Mapk8ip1-/- 
/ Jip1-/-) and wild type mice were stained with an antibody to JIP1 (Santa, Cruz 
m-300) (green) and DAPI (for DNA staining) (blue).  Images were taken using 
Leica confocal microscope.  
 
 
Figure 4.6. Wild type primary b-cells were obtained by dispersion of the isolated 
islets, and cultured in RPMI medium with 5mM glucose.  Cells were fixed with 
methanol at -20 oC and stained with an antibody to g-tubulin (red), JIP1 (Santa 
Cruz, m-300) (green) and DAPI (for DNA staining) (blue).  Images were taken 
using Leica confocal microscope. Observed nuclear staining may be a non-
specific background, since it is not observed in stained pancreas sections in 
figure 4.5. 
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Figure 3) Beta-cells show dense JIP1 staining at a single foci.
Obesity is a major risk factor for the 
development of insulin resistance and type-II 
diabetes. JIP1 (JNK-Interacting protein 1) is a 
scaffold protein that mediates JNK activation in 
response to several stress conditions including high-
fat diet. JIP1 also functions as an adapter protein for 
sub-cellular trafficking by microtubule motor proteins 
(kinesin and dynein).  Previous studies showed that 
Jip1-/- mice are protected against high fat diet 
induced obesity and insulin resistance, but the 
underlying mechanisms that account for the effects 
of JIP1-deficiency are unclear.   
In this study, we examined whether JIP1 in 
endocrine cells is important for metabolic regulation.  
We established mice with conditional Jip1 alleles and 
used Cre recombinase to obtain mice with Jip1 gene 
ablation in selected endocrine cells.  Metabolic 
phenotypes in these mice were characterized.  
Mechanistic studies were performed to identify 
whether the requirement of JIP1 for normal 
endocrine cell function reflected roles of JIP1 in 
intracellular trafficking mediated by interactions with 
cytoplasmic motor proteins (dynein and kinesin) or 
roles of JIP1 as a scaffold protein for the activation 
of JNK signaling.  The results of our analysis is 
presented in the poster.  
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Figure 2) JIP1 is not essential for vesicle docking to the membrane.
¾ JIP1 is a scaffold protein which 
mediates JNK activation in response 
to stress stimuli.1,2,3
¾Jip1-/- mice are protected against high-fat diet-
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¾A missense mutation of human Jip1 gene 
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Figure 6) Kinesin binding of JIP1 is not essential 
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Figure 4.7. Isolated islets were cultured on glass coverslips for 24-48 hours in 
RPMI medium with 5mM glucose.  After fixation with methanol at -20 oC islets 
were stained with antibodies to JIP1 (Santa Cruz m-300)(green), g-tubulin (red) 
and DAPI (for DNA staining) (blue).  Images were taken using confocal 
microscope. Arrows indicate the co-localization of JIP1 with g-tubulin.  Observed 
nuclear staining may be a non-specific background, since it is not observed in 
stained pancreas sections in figure 4.5. 
 
Electron microscopic analysis of b-cells demonstrated an increased 
occurrence of double cilia in JIP1 deficient islets (Figure 4.8.).  The existence of 
more than one primary cilium (double cilia) in a cell is an unusual finding.  
Mahjoub et al. reported that centrosome amplification induced by ectopic Plk4 
Kinase expression[79] resulted in cells with multiple primary cilia (Super-ciliated 
cells)[80].  Moreover, existence of multiple primary cilia in cells led to the 
dysregulation of ciliary signaling[81].  My preliminary data showing the possible 
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Figure 3) Beta-cells show dense JIP1 staining at a single foci.
Obesity is a major risk factor for the 
development of insulin resistance and type-II 
diabetes. JIP1 (JNK-Interacting protein 1) is a 
scaffold protein that mediates JNK activation in 
response to several stress conditions including high-
fat diet. JIP1 also functions as an adapter protein for 
sub-cellular trafficking by microtubule motor proteins 
(kinesin and dynein).  Previous studies showed that 
Jip1-/- mice are protected against high fat diet 
induced obesity and insulin resistance, but the 
underlying mechanisms that account for the effects 
of JIP1-deficiency are unclear.   
In this study, we examined whether JIP1 in 
endocrine cells is important for metabolic regulation.  
We established mice with conditional Jip1 alleles and 
used Cre recombinase to obtain mice with Jip1 gene 
ablation in selected endocrine cells.  Metabolic 
phenotypes in these mice were characterized.  
Mechanistic studies were performed to identify 
whether the requirement of JIP1 for normal 
endocrine cell function reflected roles of JIP1 in 
intracellular trafficking mediated by interactions with 
cytoplasmic motor proteins (dynein and kinesin) or 
roles of JIP1 as a scaffold protein for the activation 
of JNK signaling.  The results of our analysis is 
presented in the poster.  
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localization of JIP1 to the basal body (Figure 4.6 & 4.7), and the double primary 
cilia occurrence (Figure 4.8) in JIP1 deficient islets, suggest that JIP1 may play a 
role in the primary cilium function in b-cells.   
 
 
Figure 4.8. Pancreas section were imaged by electron microscopy as described 
in Chapter 2.3. Representative images showing primary cilium (highlighted by 
false color) in wild type and double primary cilia in JIP1 deficient samples.  
 
The localization of JIP1 to the basal body, and increased frequency of 
double cilia in JIP1 deficient islets require further experimental confirmation.  As 
discussed in section 4.2.1. evaluating JIP1 interaction partners with BioID 
method can detect possible JIP1 interaction with proteins related to the 
centrosome or primary cilium.  In addition, immunofluorescence staining of 
WT JIP1
ex∆
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dispersed primary b-cells with primary cilium marker, such as acetylated tubulin, 
or IFT88 would confirm the increased frequency of multiple primary cilia 
occurrence in JIP1 deficient b-cells.  These cells can also be evaluated under 
different glucose concentrations. 
4.2.5 JIP1, cell polarity, and insulin secretion 
In most cases, primary cilium dysfunction and cell polarity defects co-exist, 
implying that these two pathways are closely linked to each other[82].  Cell 
polarization is essential for many terminally-differentiated cell function including 
b-cells in pancreas islets.  b-cells are polarized, and organized around the 
capillaries (rosette structure) so that the insulin can be released to the capillary 
contact sites[83, 84] (Figure 4.9).  Moreover, disruption of this organization can 
alter insulin secretion from beta-cells[84]. 
                
Figure 4.9. Cartoon showing the rosette structure of polarized b-cell. b-cells align 
around the capillaries and nuclei (light purple) are positioned at the opposite site 
of the capillary contact site. 
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JNK plays a role in the Planar Cell Polarity (PCP) and Wnt signaling 
pathway[85, 86].  In addition, JIP1/JNK-mediated cargo transport in neurons was 
implicated in neuronal polarity[32].  Additionally, in consideration with the role of 
JNK in microtubule associated protein phosphorylation, and the close 
relationship between cell polarity and microtubule dynamics, it is possible that 
JNK may be involved in the regulation of b-cell polarity.                
To test if there is a decreased phosphorylation of microtubule associated 
protein STMN2 in JIP1 deficient b-cells, I stained pancreas sections from control 
and JIP1 deficient mice with an antibody against phosphorylated STMN2-Ser73 
(Figure 4.10.).  Preliminary results suggested that the amount of P-STMN2-Ser73 
is similar in control and JIP1 deficient islets.  However, a polarized localization of 
P-STMN2-Ser73 was noticeable in b-cells, where P-STMN2 was present on only 
a single side of the nucleus and mostly towards the capillary contact site in a 
rosette structure, especially in pancreas sections from glucose stimulated 
wildtype mice (Figure 4.10. upper right panel).  This finding raises the question 
whether JIP1-mediated JNK activation can play a role in the polarized 
localization of microtubule associated protein phosphorylation and local 
microtubule stability regulation in response to glucose. 
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Figure 4.10. Paraffin embedded pancreas sections from wild type and JIP1 
deficient mice (after PBS or glucose injection) were stained with an antibody 
against P-STMN2-Ser73 (DAB).  Rosette structure is highlighted by false color in 
upper right panel. P-STMN2-Ser73 staining localized asymmetrically at one side 
of the nucleus (an example is indicated by the arrow in upper left panel).  This 
localization became more structured in glucose stimulated islets, positioning 
inner side of the nucleus in rosette structures. 
	
	
 To test if the rosette structure of b-cell organization is disrupted in JIP1 
deficient islets, it is crucial to perform quantitative imaging analysis of b-cell 
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borders and nuclei, in addition to capillary cells in the islets.  Granot and Swisa et 
al. reported quantitative analysis of nuclear positioning in rosette structures of b-
cells by staining pancreas sections with a DNA marker, and antibodies to E-
cadherin (for b-cell borders), and Laminin (for capillary staining)[84].  A similar 
approach could quantitatively evaluate the subcellular localization of P-MAP in 
control and JIP1 deficient islets after PBS or glucose injection.  In addition, 3D 
visualization of islets by staining multiple serial sections would give more insight 
on the cellular-vascular organization. 
 
4.2.6 Possible functional differences of JIP1 splice/translation variants 
In Chapter 2, I have shown that the JIP1 protein is detected as two thick 
smear-like bands on immunoblots, corresponding to ~90 KD and ~110 KD sizes.  
So far, it is not known which amino acid sequences correspond to these 
differentially sized JIP1 proteins.  Previous studies showed that upon stimulation 
of cells with cytokines, the low molecular weight (LMW) JIP1 was more sensitive 
to proteosomal degradation when compared to the high molecular weight (HMW) 
JIP1, suggesting that HMW and LMW JIP1 proteins may have distinct functions 
and stability. 
Deleting exon-2 results in the loss of high molecular weight (HMW) JIP1 
protein, while low molecular weight (LMW) JIP1 is preserved.  JIP1 exon-2 is 106 
base pair in length, and its deletion with the subsequent exon1-exon3 junction 
results in frameshift and early stop codon in coding sequences starting from 
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distal exon1 and proximal exon-1.  Thus, the existence of the LMW JIP1 protein 
after JIP1 exon2 deletion suggests that either there is an alternative translation 
start site downstream of exon-2 that can by-pass the deletion and translate the 
LMW protein, or an alternative splice junction in the absence of exon-2 results in 
an in-frame codon reading.  
 
 
Figure 4.11. Cartoon representing predicted coding sequences for high molecular 
weight and low molecular weight JIP1 proteins.  Splice junction are detected by 
mRNA sequencing from brain samples. (Alter: Alternative) 
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My results and previously published data[87] suggest that the HMW JIP1 
protein band can possibly consist of at least 4 proteins (Figure 4.11.).  The slight 
difference in the size and different phosphorylation status of these JIP1 isoforms 
may cause the thick smear-like observation of JIP1 protein bands from the brain 
samples. 
The presence of a LMW JIP1 protein after Exon2 deletion supports the 
idea that the in-frame ATG at the beginning of short Exon3 junction may serve as 
an alternative translation start site coding the LMW JIP1 protein.  In addition, 
Jip1-/- mice that lack exon2 and exon3 display loss of both LMW and HMW JIP1 
proteins, showing that exon3 is required for the presence of LMW JIP1 protein.   
Sequencing of the cDNA from wildtype and JIP1 exon2 deleted samples 
identified a new splice junction between exon1 and the end of exon3.  This 
junction skips JNK binding domain on exon3.  An alternative start site on distal 
exon1, detected by published ribosome profiling data, can translate an alternative 
exon1 that has an in-frame junction with exon3. 
The high variation of JIP1 N-terminus coding sequence suggests that the 
regulation of this region at the mRNA and translational levels may regulate the 
functional specificity of JIP1 in a cell and context-dependent manner.  For 
instance, in the brain, both LMW and HMW JIP1 are observed in high 
abundancy, while in b-cells, HMW JIP1 is more prominent (Figure 2.)[88].  Our 
results show that, LMW JIP1 does not contain exon2, while its existence is 
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dependent on exon3 (exon2 and exon3 deletion results in the loss of LMW 
protein).   
 Immunoprecipitation of endogenous JIP1 proteins from various tissues 
followed by mass spectrum analysis is crucial to identify amino acid sequence of 
JIP1 proteins.  Also, by using CRISPR technology, mutating the in-frame ATG on 
exon3 to test if the presence of LMW JIP1 protein is dependent on the alternative 
translation start from exon3 could provide informative understanding. 
 
4.2.7 Role of JIP1-JNK interaction in TSH secretion 
In addition to insulin secretion, my analysis shows that JIP1 mediates 
TRH-induced TSH secretion from the anterior pituitary gland.  Abe et al. 
proposed that JIP1 can play a role in the regulation of Tsh-b expression[89].  
However, my results suggest that JIP1 is not required for Tsh-b expression, since 
control and JIP1 deficient pituitary glands show similar Tsh-b mRNA levels.  On 
the other hand, my results do not exclude a possible role for JIP1 in TRH-
induced TSH expression, or in di-urinal TSH secretion regulation.   
Our lab previously reported that deletion of JNK1 and JNK2 in the anterior 
pituitary gland results in increased TSH secretion[90].  This was accompanied by 
decreased Dio2 expression, an enzyme that converts T4 to active form T3 in the 
pituitary gland, and mediate negative feedback inhibition.  Thus, decreased 
negative feedback inhibition resulted in increased Tsh-b gene expression in 
JNK1,2 deficient anterior pituitary gland.  The results of this study suggest that 
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the regulation of Tsh-b expression by JNK is independent of JIP1, since there 
was no alteration in the gene expression in JIP1 deficient anterior pituitary 
glands.  Also, increased TSH secretion from JNK1,2 pituitary glands reported by 
Vernia et al. suggests that JNK activity may not be essential for TSH 
secretion[90].   
All JNK isoforms (JNK1, JNK2, and JNK3) are expressed in the pituitary 
gland[91].  It is therefore possible that the presence of JNK3 may compensate for 
a potential role of JNK1 and JNK2 in the hormone secretion.  Ablation of JIP1 in 
the JNK1,2 deficient anterior pituitary gland will be important to test whether JIP1 
deficiency would result in decreased TSH secretion in the absence of JNK1,2.  In 
addition, evaluating JNK3 activity in these mice would identify a possible JIP1-
JNK3 crosstalk in TSH secretion. 
 
4.2.8 JIP1-JNK pathway, autophagy, and endocrine function 
Fu et al. showed that JIP1 can mediate autophagosome trafficking and 
autolysosome formation in neurons[1].  Autophagy is implicated in the function of 
b-cells and regulation of insulin secretion[92].  It is proposed that autophagy can 
regulate islet expansion in obesity[11, 93, 94], and b-cell insulin content[10].   
Pancreas-specific ATG7 deficiency in mice results in decreased b-cell 
mass, and decreased insulin secretion[11], On the other hand, my data shows 
that JIP1 deficient mice have similar islet size and islet insulin content compared 
with controls.  This finding suggests that a severe autophagy defect in JIP1 
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deficient islets is unlikely.  However, it is possible that JIP1 may mediate 
autophagosome trafficking in b-cells, and the deficiency of JIP1 may affect only a 
subset of cellular autophagy.  Muller et al. recently showed that old insulin vesicle 
can be targeted to the autophagosomes, while young insulin vesicles are 
preferentially secreted[12].  Evaluating co-localization of JIP1, insulin vesicles, 
and LC3B, an autophagosomal marker, in b-cells would give insight on a 
possible role for JIP1 in autophagosomal degradation of old insulin vesicles. 
JNK is also implicated in the regulation of autophagy.  However, whether 
JNK activity is required for autophagy is unclear.  Wei et al. proposed that JNK is 
activated mouse embryonic fibroblasts (MEF) after starvation, and JNK-mediated 
BCL2 phosphorylation is required for Beclin1 activation autophagy induction[13].  
On the other hand, Xu et al. showed that JNK deficient primary neurons exhibit 
increased autophagy[14].   
The results in Chapter3 show that JNK is not activated by starvation in 
primary and immortalized MEF.  Moreover, JNK deficient MEF showed similar 
levels of autophagy induction compared with the control MEF under starvation 
condition.  This result suggests that JNK is not essential for autophagy induction.    
On the other hand, JNK deficient primary hepatocytes displayed increased basal 
autophagy flux, suggesting that JNK may play a role in autophagy in a cell and 
context specific manner. 
 Further studies to evaluate the basal and induced autophagy in JIP1/JNK 
deficient endocrine tissues such as islets or pituitary gland would provide more 
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insight on the role of JIP1/JNK pathway in autophagy dynamics in the context of 
hormone secretion and endocrine cell function. 
 
4.3 Concluding Remarks 
Proper functioning of endocrine cells is crucial for organismal 
homeostasis. Regulated hormone secretion is a complex mechanism, and the 
signaling pathways that fine-tune the amount and the timing of the hormone 
secretion are still unclear.   
The data presented in this study suggests that JIP1, a scaffold protein in 
cellular stress signaling pathway, mediates regulated-insulin secretion from 
pancreas b-cells in response to glucose.  Our study showing the role of JIP1-
kinesin interaction and JIP1-JNK interaction in glucose-stimulated insulin 
secretion, implies a mechanism that link cellular trafficking and stress signaling 
pathways in the regulated hormone secretion.  
 In addition to the known role of JIP1 in metabolism and insulin resistance, 
this finding is also relevant to many endocrine pathologies where excess 
hormone secretion may need inhibitory control, such as adenomas.  Identification 
of the cell-specific functions of scaffold proteins can provide a platform to 
manipulate context-specific signaling complexes, without deteriorating other 
cellular functions.  
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